Research Article

Design and Synthesis of Novel Antileishmanial Compounds

Melanie Loedige

Institute of Organic Chemistry, University of Würzburg, Am Hubland, 97074 Würzburg, Germany

Correspondence should be addressed to Melanie Loedige; mloedige@upenn.edu

Received 8 September 2014; Accepted 4 December 2014

Academic Editor: Jochen Lehmann

Copyright © 2015 Melanie Loedige. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

According to the WHO, infectious diseases, and in particular neglected tropical diseases in poor developing countries, still play a significant role in a vast number of deaths reported worldwide. Among them, leishmaniasis occurs as a complex and clinically diverse illness caused by protozoan *Leishmania* species which are transmitted through the bite of sandflies. They develop through a complex life cycle, from promastigotes in sandflies to amastigotes in humans. The severity of disease is determined by the type of infecting *Leishmania* species and also depends strongly on whether the parasite infection leads to a systemic involvement or not. Since the sensitivity towards diverse medicaments highly differs among the *Leishmania* species, it is advantageous to treat leishmaniasis with species-specific drugs. Towards this goal we report a synthetic methodology and characterization of novel small molecular agents active against both forms of *L. major*. This synthetic approach allows for rapid access to new active antileishmanial drug templates and their first derivatives in moderate to very good yields. Although the compounds reported here are bioactive, the detailed biological results are part of a more comprehensive study and will be reported separately by our collaborators.

1. Introduction

Infectious diseases are still a major concern worldwide [1, 2]. In spite of the improved living conditions and advances in drug therapy leading to an increased protection from pathogen caused illnesses in industrialized countries, the ongoing research for new drugs is particularly important due to development of resistance to microorganisms [3], creation of new types of pathogenic agents, and the ease of transmission by globalization [2]. In the poor developing nations, which make up almost half of the world population, these kinds of diseases wreak havoc, eventually resulting in death [2]. The available medicaments against the so-called neglected tropical diseases such as leishmaniasis are often either harmful because of their side effects [4], not sufficiently effective, or expensive [5].

Leishmaniasis is caused by about 20 different protozoan *Leishmania* species [6] which are transmitted to humans through the bite of female phlebotomine sandflies [7, 8]. During the dimorphic life cycle, the parasites develop in the guts of the sandfly into promastigotes [9]. Once the parasite is transmitted to humans, they grow up within the parasitophorous vacuole of human macrophages into amastigote

forms [10], followed by host cell destruction to release *Leishmania* parasites for repeated infection of macrophages [11]. The severity of disease is in general determined by the grade of systemic involvement and in particular by the type of infecting *Leishmania* species [12, 13]. The clinical picture shows diverse forms of leishmaniasis (visceral leishmaniasis, mucocutaneous leishmaniasis, and various cutaneous forms [6]). With no effective vaccines [14] and no prophylactic treatments currently available [15], with the development of resistance against the established drugs [16], and with irreversible and life-threatening side effects, leishmaniasis certainly paints a grim picture [6]. Most of the drugs such as stibogluconate, amphotericin B, pentamidine, and paromomycin need to be applied parenterally which complicates the administration, and miltefosine is the only orally applicable medicament so far (Figure 1) [17].

Currently affecting about 350 million people with estimated 1.3 million new cases reported annually in 98 countries [18, 19] the search for new orally bioavailable and cost-effective medicaments with good toxicity profiles against leishmanial infections is extremely important [20].

Therefore, we have reported here the synthesis and characterization of novel small molecular compounds such as

FIGURE 1: The antileishmanial drugs miltefosine (1) and pentamidine (2) used as reference drugs in the bioactivity study against *L. major*.

molecules 5, 11, 12, and 15 as potential lead structures for the treatment of leishmaniasis (*L. major*). The synthetic approach described here has the advantage of being amenable to rapid synthesis of novel antileishmanial drug templates and their derivatives. Although the new molecules reported in this work showed good biological activity against both forms of *L. major* in the range of the standard drugs miltefosine and pentamidine or even better, the detailed biological results are part of a more comprehensive study and will be reported separately by our collaborators [21].

2. Results and Discussion

2.1. Background. Known heterocyclic structures such as quinolines in general [23, 24], 4-amino-7-chloroquinoline moieties [25] with, for example, chloroquine (3) [26], and also 6-methoxy-8-aminoquinolines with primaquine (4) [27–31] as well as other heterocyclic substituents have already been described as antileishmanial active (Figure 2).

Thus, our intention towards developing new antileishmanial drugs was to attach variable linkers to these heterocyclic structures which would enable us to link in subsequent synthetic steps other known antileishmanial active heterocyclic moieties. Since the first as linker part synthesized compound (*rac*)-5 already showed activity in the range of the standard drugs miltefosine (1) and pentamidine (2), we started to synthesize derivatives of 5 with varied linker according to chain length (4 and 10 carbon atoms), varied type of linkage (branched and unbranched), different terminal substituents in position A (hydrophobic, hydrophilic, and hydrogen bond forming substituents and aromatic moieties), and also cyclic structures. Eventually, also the structural part which was assumed as pharmacophore (substituent B) of these new templates was analogized (Figure 3).

2.2. Chemistry

2.2.1. General Synthetic Procedures. All synthesized novel antileishmanial compounds were based on the plain building block (*rac*)-5 (Scheme 1) and their general structure with various R^1 , R^2 , R^3 , and R^4 substituents which are shown in Figure 4.

All derivatives were synthesized from commercially available precursors purchased from Sigma Aldrich with different chain lengths according to standard chemical procedures,

FIGURE 2: Structures of primaquine ((*rac*)-4) and chloroquine ((*rac*)-3); in black the corresponding 4-amino-7-chloroquinoline moiety and the 6-methoxy-8-aminoquinoline moiety.

FIGURE 3: Novel antileishmanial template (*rac*)-5 and its general scheme.

FIGURE 4: General structure of novel antileishmanial active compounds that were synthesized in this work.

followed by several conversion steps to obtain the derivatives needed for structure activity relationship studies. The general synthetic procedures are as follows.

The primary amine function of benzylamine (Scheme 1) was reacted with Boc_2O in MeCN (dry) or 3,3-dimethylbutanoyl chloride in DCM (dry) at temperatures from 0°C up to 25°C to give the respective protected starting materials. Deprotonation with NaH in DMF (dry) at 0°C and subsequent reaction with (*rac*)-1,4-dibromopentane (Schemes 1 and 2), 1,4-dibromobutane, and 1,10-dibromodecane (Scheme 3) at 0°C to 25°C gave the bromine derivatives and their elimination products. The terminal bromine atom was used for the introduction of different nitrogen containing substituents such as azide, amine, and heterocycles by nucleophilic substitution reactions (Scheme 1).

In general, the bromine compounds were converted to azides using NaN_3 in DMF (dry) at room temperature with subsequent reduction to the corresponding amines by Staudinger reaction using a two-step synthetic protocol. The bromine and also the amine function were coupled with different heterocyclic moieties by nucleophilic substitution reactions.

In order to investigate which functional groups of the assumed pharmacophore were required for activity, analogs with diverse terminal functional groups in position B were synthesized. The original *tert*-butoxycarbonylbenzylamino

SCHEME 1: Synthesis of derivatives with a branched alkyl side chain consisting of 5 carbon atoms (**5**, **7** to **10**) and the 4-amino-7-chloroquinolinyl substituted derivatives (**11** and **12**) with antileishmanial activity. Reagents and conditions: (a) Boc_2O , MeCN (dry), 0–25°C; (b) (*rac*)-1,4-dibromopentane, NaH, DMF (dry), 0–25°C; (c) NaN_3 , DMF (dry), 25°C; (d) TFA, DCM, 25°C; (e) PPh_3 , MeOH (dry), 25°C; (f) 4,7-dichloroquinoline, $\text{Pd}_2(\text{dba})_3$, $\pm$ -BINAP, KOtBu, 1,4-dioxane (dry), 85°C; (g) TFA, DCM, 25°C.

SCHEME 2: Synthesis of the compounds **15** and **16** with additionally benzylated aromatic amine functions. Reagents and conditions: (a) Boc_2O , MeCN (dry), 0°C; (b) benzyl bromide, NaH, DMF (dry), 0–25°C.

SCHEME 3: Synthesis of the cyclized products (*rac*)-**17** and (*rac*)-**18** for structure activity relationship studies. Reagents and conditions: (a) TFA, DCM, 25°C; (b) dibenzylamine, acetone, 60°C.

group was replaced by a *N*-benzyl-3,3-dimethylbutanamide (Scheme 7) functionality as well as by a phthalimide group (Scheme 8).

Compounds with a terminal phthalimide functionality in position A were synthesized by the reaction of (*rac*)-1,4-dibromopentane with potassium phthalimide in acetone at 60°C, followed by the introduction of the azide function using NaN_3 in DMF (dry) at room temperature (Scheme 5).

Cyclized structures were obtained by deprotection of **5** using TFA in DCM and by reaction of (*rac*)-1,4-dibromopentane with dibenzylamine in acetone at 60°C (Scheme 2).

2.2.2. Results

(1) *Synthesis of the Linker Moiety and the 4-Amino-7-chloroquinoline Substituted Compounds.* For the synthesis of the linker molecule (Figures 3 and 4), we introduced the Boc protecting group to benzylamine according to a literature known protocol [32] using Boc_2O in MeCN to give compound **6** in 98% yield, followed by the deprotonation with NaH and by a nucleophilic substitution reaction with 1,4-dibromopentane in DMF (dry) at temperatures from 0°C up to 25°C (Scheme 1, step b). The major and the minor products of the reaction were (*rac*)-**5** and the elimination product **7**. The yield of the bromine compound (*rac*)-**5** depended on the following factors: (a) the equivalents of NaH, (b) temperature, (c) reaction time, and (d) the total amount of substance in the reaction mixture. Compound (*rac*)-**5** was obtained in varying yields from 56% to 77%, also obtaining elimination

product **7**. Interestingly, since the biological investigation showed that compound (*rac*)-**5** was already antileishmanial active in the concentration range of the reference substances miltefosine (**1**) and pentamidine (**2**), we studied the structure activity relationships of those simple linkage molecules in more detail. The linker molecule was varied by the successful introduction of the azide functional group by using NaN₃ in DMF (dry) at room temperature to give compound (*rac*)-**8** in 97% yield (Scheme 1, step c). (*rac*)-**8** was further structurally modified in two ways: (a) by reacting with TFA in DCM at room temperature to remove the Boc protecting group to (*rac*)-**9** (95%, Scheme 1, step d) and (b) by Staudinger reaction using PPh₃ in MeOH (dry) at room temperature yielding in amine (*rac*)-**10** (96%, Scheme 1, step e). The free amine function of (*rac*)-**10** was essential for the coupling to 4,7-dichloroquinoline by a Buchwald-Hartwig amination reaction protocol using Pd₂(dba)₃ as catalyst, the ligand $\pm$ -BINAP with basic KOtBu in 1,4-dioxane (dry) at 85°C, to give product (*rac*)-**11** in 63% (Scheme 1, step f), which was Boc deprotected to substance (*rac*)-**12** in 88% yield (Scheme 1, step g).

Derivatives with a tertiary aromatic amine function in position A and with two differently substituted terminal nitrogen atoms in position B were produced (Scheme 2). The Boc group was introduced to obtain **14** and then reacted with NaH followed by the benzyl bromide addition in DMF (dry) to give compounds **15** (23%) and **16** (23%) with the additionally benzylated aromatic amine function.

Since the bromine compound (*rac*)-**5** showed antileishmanial activity, we checked if an *in situ* Boc deprotection and following nucleophilic substitution during the biotests might create (*rac*)-**17** which could have shown activity instead of compound (*rac*)-**5**; thus the synthesis of cyclized derivatives followed (Scheme 3). By using TFA in DCM at room temperature (*rac*)-**5** was converted to an intermediary benzylated amine that instantly cyclized to (*rac*)-**17** in 86% yield. A similar but a quaternary amine compound (*rac*)-**18** (54%) was obtained by using (*rac*)-1,4-dibromopentane and dibenzylamine in acetone at 60°C.

(2) *Variation of the Linker and of Substituents in Position A*. Since we assumed that the Boc group and the benzyl functionality attached to the terminal amine function in position B were the pharmacophore moiety, further derivatives with variable linker were synthesized preserving this moiety in position B. The reaction conditions that were previously successful in the synthesis of (*rac*)-**5** from (*rac*)-1,4-dibromopentane did not work for the reaction of compound **6** with 1,2-dibromopropane, and hence a two-carbon-atom side chain analog of (*rac*)-**5** could not be synthesized for structure activity relationship studies. The influence of the branched side chain with the additional methyl group and the side chain length was moreover investigated by synthesizing analogs with an unbranched side chain and side chain length of four and 10 carbon atoms. Using the reaction conditions previously successful in the synthesis for (*rac*)-**5**, the unbranched starting materials 1,4-dibromobutane and 1,10-dibromodecane gave in general lower yields (Scheme 4). The bromine compounds **19** and **20** each were obtained in 27% and 44% yield, respectively, and the elimination products

SCHEME 4: Synthesis of four- and 10-carbon-atom-long unbranched derivatives (**19** to **26**). Reagents and conditions: (a) 1,4-dibromobutane or 1,10-dibromodecane, NaH, DMF (dry), 0–25°C; (b) NaN₃, DMF (dry), 25°C; (c) 1: NaN₃, PPh₃, 2: KOH, DMF (dry), 25°C.

21 and **22** were obtained in 9% and 5% yield, respectively (Scheme 4, step a). The conversion to the corresponding azides by NaN₃ in DMF (dry) at room temperature gave **23** (86%) and **24** (95%) (reaction monitored by NMR spectroscopy, Scheme 4, step b). Using a one-pot reaction procedure, compounds **19** and **20** were stirred separately, first with NaN₃ and PPh₃ in DMF at room temperature in an *in situ* Staudinger reaction and a final KOH addition step which hydrolyzes the DMF stable intermediary iminophosphorane compounds resulting in the formation of amines **25** (47%) and **26** (39%).

(3) *Synthesis of the 6-Methoxy-8-aminoquinoline Substituted Compounds*. Primaquine (**4**) [27] and its derivatives [28, 29] (Sitamaquine [30] and Tafenoquine [31]) have already been described as antileishmanial active. In order to introduce a 6-methoxy-8-aminoquinoline moiety to the assumed pharmacophore, primaquine (**4**) was protected by a Boc group at the terminal amine functional group using Boc₂O in DCM (dry) at 0°C in 94% yield ((*rac*)-**27**, Scheme 5, step a), followed by the introduction of the benzyl group to complete the assumed pharmacophore moiety using NaH in DMF (dry) and benzyl bromide to give (*rac*)-**28** in 79% yield (Scheme 5, step b).

(4) *Linkage to Various Heterocyclic Substituents*. As a monocyclic, aromatic nitrogen containing heterocycle for structure activity relationship studies, imidazole was introduced to the bromine derivative (*rac*)-**5** by using NaH in DMF (dry) to give compound (*rac*)-**29** in 50% yield. Using equal reaction conditions and pyrrole as heterocyclic component, the desired product was not obtained. The introduction of the phthalimide heterocycle using potassium phthalimide in DMF at room temperature gave product (*rac*)-**30** in good yields (81%, Scheme 6).

(5) *Analogs of the Pharmacophore Moiety*. Apart from varying the terminal substituents in position A, we also synthesized structural analogs of the assumed pharmacophore moiety in position B and replaced single atoms in order to investigate the significance of both the Boc and benzyl group in generating antileishmanial activity. Towards this, one oxygen atom

SCHEME 5: Synthesis of the 6-methoxy-8-aminoquinoline containing derivative (rac)-28. Reagents and conditions: (a) Boc_2O , DCM (dry), 0°C ; (b) benzyl bromide, NaH, DMF (dry), $0-25^\circ\text{C}$.

SCHEME 6: Introduction of additional heterocyclic moieties to the assumed pharmacophore (compounds 29 and 30) for structure activity relationship investigations. Reagents and conditions: (a) imidazole, NaH, DMF, 25°C ; (b) potassium phthalimide, DMF (dry), 25°C .

of the Boc group was replaced by a carbon atom to examine the effect of the decreased free rotatability of the *tert*-butyl residue and the loss of the hydrogen bond acceptor (Figure 5).

The key intermediate 31, the *N*-benzyl-3,3-dimethylbutanamide, was obtained in 94% yield using benzylamine and 3,3-dimethylbutanoylchloride (Scheme 7) and converted to compound (rac)-32 in very low yields of 5% using NaH, (rac)-1,4-dibromopentane in DMF (dry) at temperatures from 0°C up to 25°C where the elimination product 33 was obtained as the main product (22%). The introduction of the azide functionality using NaN_3 in DMF (dry) produced compound (rac)-34 (95%), followed by Staudinger reaction to obtain the amine (rac)-35 (89%), both in very good yields. The intended coupling to 4,7-dichloroquinoline under neat conditions at 120°C failed so far, and a Buchwald-Hartwig amination has not been tried yet but it is expected to be successful.

Compounds with a phthalimide group (36 to 39) instead of the assumed pharmacophore moiety in position B were designed as analogs with less steric hindrance and with the benzyl group involved in a fixed ring structure to decrease rotatability (Figure 6).

A reaction between potassium phthalimide and (rac)-1,4-dibromopentane [33] in acetone (dry) at 60°C produced not only the bromine derivate 36 (72%) but also the elimination product 37 and the disubstituted compound 38 as the minor products. Using NaN_3 in DMF (dry) gave product 39 in 90% yield. Because of the lack of biological activity, further derivatization of 39 was not pursued (Scheme 8).

In summary, the novel pharmacophore type present in the compounds 6 to 15 was investigated for its antileishmanial

FIGURE 5: Bioisostere replacement [22] of one oxygen atom (A) by a methylene group (B).

FIGURE 6: Corresponding components (in green; linkage positions in red) of the motif B and the designed compound C.

activity against promastigotes and amastigotes of *Leishmania major*. Since the building block (rac)-5, previously intended as linkage moiety, already showed activity against *L. major* in the concentration range of the reference substances miltefosine (1) and pentamidine (2), we examined the structure activity relationships of this novel substance class by the synthesis of various analogs.

2.3. Discussion. Derivatives of the substance (rac)-5 with variation of both terminal substituents in positions A and B were synthesized to examine the necessary structural elements for antileishmanial bioactivity. The plain starting material compound 6 showed no activity at all against promastigotes of *L. major* hinting at the requirement of a terminally substituted (position A) alkyl side chain for activity. If the side chain was not substituted as in but-3-enyl-(21), dec-3-enyl-(22), or pent-3-enyl-residues (7), the molecule showed very little to no activity (Table 1). Thus, a nonsubstituted aliphatic side chain does not introduce activity. Antileishmanial activity was observed for a lipophilic bromine substituent (as, e.g., in compounds 5, 19, 20, and 32), an azide substituent (as, e.g., in compounds 8, 23, 24, and 34), and a terminal amine function (as, e.g., in compounds 10, 25, 26, and 35). Compounds (rac)-5, 8, 20, and 26 showed antileishmanial activity values in the same range as the reference substances miltefosine (1), the solely orally applicable medicament against leishmaniasis [34], and

SCHEME 7: Synthesized analogs (**31** to **35**) of the assumed pharmacophore moiety. Reagents and conditions: (a) 3,3-dimethylbutanoylchloride, NEt_3 , DCM (dry), 0–25°C; (b) (*rac*)-1,4-dibromopentane, NaH, DMF (dry), 0–25°C; (c) NaN_3 , DMF (dry), 25°C; (d) PPh_3 , MeOH (dry), 25°C.

SCHEME 8: Pharmacophore replacement using a phthalimide motif. Reagents and conditions: (a) (*rac*)-1,4-dibromopentane, acetone (dry), 60°C; (b) NaN_3 , DMF (dry), 25°C.

pentamidine (**2**), with (*rac*)-**5** showing the highest activity. The cyclization products **17** and **18** were inactive (Table 2). If the methyl group in position 4 was lacking, compounds **19**, **21**, and **23** lost activity against promastigotes of *L. major*. The derivatives **22** and **24** without a terminal methyl group and with a longer side chain consisting of 10 carbon atoms showed no activity and **20** and **26** showed decreased activity (Table 1).

The terminal substituents were varied using a 4-amino-7-chloroquinolinyl (**11** and **14**), a 6-methoxy-8-aminoquinolinyl (**27** and **28**), a phthalimide (**30**), and an imidazolyl substituent (**29**; Table 2). A larger, lipophilic, nitrogen containing substituent that could build hydrogen bonds and that could cause a trapping of the compound by protonation in acidic compartments of the *Leishmania* organism increased the activity (**11**). For substance **14** with a higher steric hindrance and higher lipophilic qualities caused by the benzyl group attached to the 4-amino nitrogen atom, the activity compared to compound **11** decreased. If the same side chain as of **11** was attached to the quinoline nitrogen atom, compound **40** [35] showed also decreased activity. Substituents such as the 6-methoxy-8-aminoquinoline moiety showed no activity at all, and the terminal phthalimide residue **30** and an imidazolyl substituent as in compound **29** showed no activity. Similar to **11**, compound **29** possessed the imidazolyl moiety which also could be enriched in acidic compartments as described for chloroquine [36] but showed no activity in comparison to the bicyclic derivative **11**, hinting at the fact that a proton-triggered enrichment in acidic compartments by protonation

may not be the main reason for the activity of aminoquinoline substituted compounds. A slightly more spatially demanding substituent was introduced by a nonprotonable phthalimide group, but compound **30** was not active.

The bioactivities vary widely with the diverse terminal substituents and thus it can provide a hint about the nature of very specific interactions with cellular structures of the *Leishmania* species. The ability to build hydrogen bonds seems to be essential for the bioactivity values. The quinoline nitrogen atom of compound **11** could be accessible to form hydrogen bonds with H-bond donors (Figure 7). In contrast, the basic quinoline nitrogen atom of compound **28** has an opposite orientation to that in **11** and thus could be less capable of building hydrogen bonds. The free rotatability around the C,N-axes (Figure 7) is probably limited by intramolecular hydrogen bonds which could fix the molecule in a particular conformation.

Due to the free rotatability around two C,N-axes of compounds **11** and **12**, a higher flexibility for the spatial arrangement of the substituents in the target environment might be given compared to compounds **29** and **30**. The nitrogen atoms of **29** and **30** as well as the quinoline nitrogen atoms of **11** and **28** are included as part of the ring structure. The nonincluded NH-function of **11**, but rather not of **28**, could contribute as hydrogen bond donor to a possible interaction with the unknown target.

In conclusion, we hypothesize that the interaction of the newly synthesized novel antileishmanial compounds with

TABLE 1: Plain open-chain aliphatic structures with diverse terminal substituents and altered side chain lengths; given bioactivities are against promastigotes of *L. major* in comparison to the reference substances miltefosine (1) and pentamidine (2).

Compound	<i>n</i>	R ¹	R ²	R ³	R ⁴	Bioactivity

6						Inactive
5	1	Me	Br	Boc	Bn	Active
7	1	=CH ₂	H	Boc	Bn	Inactive
8	1	Me	N ₃	Boc	Bn	Active
9	1	Me	N ₃	H	Bn	Inactive
10	1	Me	NH ₂	Boc	Bn	Inactive
19	1	H	Br	Boc	Bn	Inactive
20	7	H	Br	Boc	Bn	Active
21	0	=CH ₂	H	Boc	Bn	Active
22	6	=CH ₂	H	Boc	Bn	Inactive
23	1	H	N ₃	Boc	Bn	Inactive
24	7	H	N ₃	Boc	Bn	Inactive
25	1	H	NH ₂	Boc	Bn	Inactive
26	7	H	NH ₂	Boc	Bn	Active

FIGURE 7: A comparison of rotatability of compounds 11, 28, 29, and 30, with diverse terminal substituents. 29 and 30 possess only one C,N-axis (rotatability shown in red curved arrows) in comparison to the two-armed compounds 11 and 28; the quinoline nitrogen atom of compound 11 could form intermolecular hydrogen bonds (shown as green straight arrows), whereas the rotatability in compound 28 might be restricted possibly due to the formation of intramolecular hydrogen bond interactions (pink-colored).

the unknown target on the protozoan might be influenced by the lipophilicity and size as well as the distance between the substituents in positions A and B, their flexible spatial orientation, and their ability to interact *via* hydrogen bonds.

To clarify the importance of the original *tert*-butoxycarbonylbenzylamino substituent for the bioactivity, the four terminal functional groups which were used initially in position A (bromine, azide, amine substituent, and the terminal double bond) were retained, and the assumed pharmacophore moiety in position B was varied (Figure 8).

The Boc- and benzyl-substituted amine function was replaced by a *N*-benzyl-3,3-dimethylbutanamide residue (31)

which resulted in decrease in bioactivity for compound 32 relative to 5 and for 34 in comparison to 8 (Figures 8 and 9, Table 3). Compounds 31 and 6 showed no activity. These observations emphasize the need for hydrogen bond formation and of more freely rotatable bonds around the C,N-axis. The oxygen atom of the Boc group seems to be essential for the interaction (Figure 8). The introduction of a phthalimide function leads to a drastic decrease in activity for all compounds (36, 37, 38, and 39) (Figure 10, Table 4).

We also investigated the activity of both the Boc and benzyl group as in the compounds 8/9, 11/12, 15/16, 27/28, and 40/41. The removal of the Boc group caused a significant loss in activity. Compound 8 lost all activity by removal of the Boc group (9) and substance 12 with a 4-amino-7-chloroquinolinyl substituent showed a significant decrease in comparison to molecule 11. The 6-methoxy-8-aminoquinoline derivatives 27 and 28 showed no activity against promastigotes of *L. major*. Similar to the initial observations, the removal of the Boc group from the 4-amino-7-chloroquinolinium salt 40 leads to a decrease of activity 41 [35], and loss of the benzyl group leads to an activity loss of 15 to 16. This shows that it is extremely essential for the Boc and benzyl group to be attached to the amine function in order for these novel molecules to show antileishmanial activity against *L. major*.

The four most active compounds against promastigotes of *L. major* were also tested against amastigotes and showed even higher activity values. The bromine derivative 5 as a simple representative of the new substance class was active in the same concentration range as the reference substances miltefosine (1) and pentamidine (2), whereas azide 8 already showed a slightly higher activity against amastigotes. The most active representatives against promastigotes with a 4-amino-7-chloroquinoline substituent 11 and 12 showed higher activity against amastigotes than promastigotes with

TABLE 2: Cyclized substances and heterocyclic structures as terminal substituents with a side chain length of 4 carbon atoms; given bioactivities are against promastigotes of *L. major* in comparison to the reference substances miltefosine (1) and pentamidine (2).

Compound	<i>n</i>	R ¹	R ²	R ³	R ⁴	Bioactivity
17						Inactive
18						Inactive
11	1	Me		Boc	Bn	Active
12	1	Me		H	Bn	Active
29	1	Me		Boc	Bn	Inactive
30	1	Me		Boc	Bn	Inactive
14	1	H		Boc	Bn	Active
15	1	H		Boc	H	Inactive
27	1	Me		Boc	H	Inactive
28	1	Me		Boc	Bn	Inactive

TABLE 2: Continued.

Compound	<i>n</i>	R ¹	R ²	R ³	R ⁴	Bioactivity
40	1	H		Boc	Bn	Active

FIGURE 8: Compound 5 and its pharmacophore analogs 32 and 36.

TABLE 3: Plain open-chain aliphatic analogs with *N*-benzyl-3,3-dimethylbutanamide functionality; given bioactivities are against promastigotes of *L. major* in comparison to the reference substances miltefosine (1) and pentamidine (2).

Compound	R ¹	R ²	Bioactivity
31			Inactive
32	Me	Br	Active
33	=CH ₂	H	Not determined
34	Me	N ₃	Active
35	Me	NH ₂	Inactive

FIGURE 9: General structure of analogs of the assumed pharmacophore moiety having a *N*-benzyl-3,3-dimethylbutanamide functionality.

11 showing slightly higher activity while **12** was significantly more active. The activity values of those compounds against promastigotes may be probably correlated with activities against amastigotes; amastigotes seem to react stronger in the case of the compounds **5**, **8**, **11**, and **12**. Investigation of bioactivity against *L. donovani* in the presence of these novel compounds showed no significant activities for all synthesized compounds, thus showing that these newly synthesized compounds might be highly selectively active against *L. major*.

2.4. Conclusion. We have synthesized and characterized a novel class of compounds with highly selective activity

TABLE 4: Pharmacophore analogs with a phthalimide functionality; given bioactivities are against promastigotes of *L. major* in comparison to the reference substances miltefosine (1) and pentamidine (2).

Compound	R ¹	R ²	Bioactivity
36	Me	Br	Inactive
37	=CH ₂	H	Inactive
38	Me		Inactive
39	Me	N ₃	Inactive

FIGURE 10: General structure of analogs of the assumed pharmacophore moiety with a phthalimide functionality.

against *L. major*. We also investigated the structure activity relationship against promastigotes of *L. major* and compared the activity values of promastigotes to the obtained activities of amastigotes. Terminal substituents in position A and the assumed pharmacophore moiety in position B were varied.

The most active substances were the 4-amino-7-chloroquinolinyl substituted compound **11**, followed by the *N*-benzylated derivative **15**, prototype compound **5**, and the Boc deprotected compound **12** (Scheme 9). The bromine substituted prototype substance **5** showed already good activity against promastigotes and amastigotes of *L. major* in the same concentration range as the reference substances miltefosine (1) and pentamidine (2).

The observed bioactivities and the short synthesis routes provide an excellent method for screening new drug targets

SCHEME 9: All active molecules of the study and reference drugs miltefosine (1) and pentamidine (2) in order from highest (11; 2.9 times more active than 1) to lowest (21; 2.8 times less active than 1) activity against promastigotes of *L. major* (against amastigotes of *L. major*: 12 < 11 < 8 < 5).

for activity against leishmaniasis in general and *L. major* in particular.

2.5. Experimental Section

2.5.1. General Information. All used solvents were distilled before use. Commercially available material was purchased from Sigma Aldrich and used without further purification. Thin-layer chromatography was carried out using silica gel 60 F₂₅₄ or alumina with fluorescent indicator. Detection of the compounds was achieved by fluorescence quenching at 254 nm, fluorescence at 356 nm, or staining with iodine or ninhydrin. Flash chromatography was performed using silica gel (20–63 mesh), deactivated silica gel (20–63 mesh; 7.5% ammonia), or ICN neutral or basic alumina, deactivated with 15% H₂O. NMR spectra were obtained on a Bruker DMX 600 apparatus and are reported in ppm relative to internal solvent signal with coupling constants (*J*) in Hertz (Hz). Spectra were usually obtained at 25°C, and compounds 19–25 and 26 were measured at (calibrated) 2°C or 3°C, respectively. EI mass spectrometry was carried out on a Finnigan MAT 8200; ESI-HRMS was measured on a Bruker Daltonik micrOTOF-focus.

2.5.2. Synthesis and Characterization of Antileishmanial Compounds

tert-Butyl Benzylcarbamate (6) [32]. Boc₂O (43.890 g, 0.201 mol) was added to a solution of benzylamine (19.620 g, 0.183 mol, and 20.0 mL) in MeCN (dry, 100 mL) at 0°C and the reaction mixture was stirred for 3 hours at 25°C. The mixture was concentrated, and the residue was suspended

in aqueous NaOH solution and exhaustively extracted using DCM. The combined organic extracts were dried (MgSO₄), filtered, and concentrated. Compound 6 (37.022 g, 98%) was obtained as colorless crystals. Mp 56°C (DCM)—IR (ATR-FTIR): $\tilde{\nu}$ = 3338 (w), 3304 (w), 3063 (w), 3035 (w), 2979 (w), 2930 (w), 2361 (w), 2341 (w), 1737 (w), 1701 (w), 1674 (s), 1607 (w), 1587 (w), 1539 (m), 1495 (w), 1452 (m), 1388 (w), 1364 (m), 1328 (w), 1310 (w), 1268 (m), 1252 (m), 1206 (w), 1163 (m), 1136 (m), 1081 (w), 1051 (m), 1027 (m), 1018 (w), 947 (w), 929 (w), 915 (w), 863 (m), 817 (w), 765 (w), 746 (m), 723 (m), 695 (s), 656 (m), 630 (w), 616 (w) cm⁻¹—¹H-NMR (400 MHz, CDCl₃): δ = 1.57 (s, 9 H, *t*Bu-Me), 4.29 (s, 2 H, CH₂Ph), 4.79 (s, broad, NH), 7.21–7.32 (m, 5 H, Ph-H) ppm—MS (EI, 70 eV): *m/z* (%) = 151.1/150.1 [M-C₄H₉]⁺ (91/100), 107.1/106.1 [M-C₅H₉O₂]⁺ (5/38), 92.1/91.1 [C₇H₇]⁺ (5/63), 58.1/57.1 [C₄H₉]⁺ (4/90)—HRMS (ESI) calcd. [M+Na]⁺ 230.11515; found 230.11507.

tert-Butyl Benzyl(4-bromopentyl)carbamate (5). NaH (955.2 mg of a 55% oily dispersion, 21.89 mmol) was added in portions to a solution of compound 6 (1.479 g, 7.14 mmol) in DMF (dry, 30 mL) at 0°C under nitrogen atmosphere and the reaction mixture was stirred for 30 min at 0°C. (*rac*)-1,4-Dibromopentane (3.610 g, 15.70 mmol, and 2140 μ L) was added and stirred for 90 min at 0°C and the mixture was allowed to warm up to 25°C. After 5 hours of stirring, the excess of NaH was carefully hydrolysed using water and the mixture was exhaustively extracted with dichloromethane. The combined organic extracts were dried (MgSO₄), filtered, and concentrated. The solvent residue was removed azeotropically as a mixture with toluene. Purification with flash column chromatography on silica gel (petroleum ether/EtOAc 20:1) gave 5 (1.965 g, 77%) as colorless oil. IR (ATR-FTIR):

$\tilde{\nu}$ = 2972 (w, br), 2926 (w, br), 2358 (w, br), 2341 (w, br), 1687 (s), 1495 (w), 1453 (m), 1413 (m), 1391 (w), 1378 (w), 1364 (m), 1282 (w), 1242 (m), 1159 (s), 1134 (s), 1090 (w), 1074 (w), 1049 (w), 1028 (w), 964 (w), 898 (w), 872 (m), 818 (w), 768 (w), 733 (m), 698 (m), 670 (w), 632 (w), 615 (w) cm^{-1} — ^1H -NMR (600 MHz, CDCl_3): δ = 1.45 (d, 9 H, *t*Bu-Me), 1.61 (m, 1 H, 2-H), 1.65 (d, $^3J_{\text{H-H}}$ = 6.66 Hz, 3 H, 5-Me), 1.70–1.72 (m, 3 H, 2-H, 3- CH_2), 3.12–3.24 (m, 2 H, 1-H), 4.06–4.10 (m, 1 H, 4-H), 4.36–4.42 (m, 2 H, CH_2Ph), 7.21–7.25 (m, 3 H, Ph-H), 7.29–7.31 (m, 2 H, Ph-H) ppm— ^{13}C -NMR (150 MHz, CDCl_3): δ = 26.25 (C-2), 26.55 (C-2), 26.68 (Me), 28.64 (*t*Bu-Me), 38.34 (C-3), 45.73 (C-1), 49.98 (NCH_2Ph), 50.46 (NCH_2Ph), 51.26 (C-4), 51.62 (C-4), 79.98 (*t*Bu-C), 127.38 (*o*-Ph-CH), 127.95 (*p*-Ph-CH), 128.69 (*m*-Ph-CH), 138.52 (Ph-C), 138.68 (Ph-C), 155.88 (Boc CO), 156.21 (Boc CO) ppm—MS (EI, 70 eV): m/z (%) = 301.2/300.2/299.2 [$\text{M}-\text{C}_4\text{H}_8$] $^{+}$ (28/7/28), 220 [$\text{M}-\text{C}_4\text{H}_8-\text{Br}$] $^{+}$ (15)—HRMS (ESI) calcd. [$\text{M}+\text{Na}$] $^{+}$ 378.10391; found 378.10391.

The elimination product (*E*)-*tert*-butyl benzyl(*pent*-3-enyl)carbamate (**7**, 375.9 mg, 19%) was obtained as colorless oil. IR (ATR-FTIR): $\tilde{\nu}$ = 2974 (w), 2930 (w), 2360 (w), 2342 (w), 1691 (s), 1605 (w), 1495 (w), 1454 (m), 1411 (m), 1364 (m), 1290 (w), 1242 (m), 1164 (s), 1134 (m), 1074 (w), 1028 (w), 1000 (w), 965 (m), 876 (m), 771 (w), 731 (m), 698 (m), 668 (w), 639 (w), 629 (w), 620 (w), 608 (w) cm^{-1} — ^1H -NMR (600 MHz, CDCl_3): δ = 1.41–1.48 (d, 9 H, *t*Bu-Me), 1.61 (d, 3 H, $^3J_{\text{H-H}}$ = 6.00 Hz, Me), 2.12–2.17 (m, 2 H, 2-H), 3.11–3.21 (m, 2 H, 1-H), 4.38–4.43 (m, 2 H, CH_2Ph), 5.31–5.41 (m, 2 H, 3-H, 4-H), 7.20–7.23 (m, 3 H, *o*-Ph-H, *p*-Ph-H), 7.28–7.31 (m, 2 H, *m*-Ph-H) ppm— ^{13}C -NMR (150 MHz, CDCl_3): δ = 18.21 (Me), 28.65 (*t*Bu-Me), 31.43 (C-2), 31.82 (C-2), 46.71 (C-1), 46.83 (C-1), 50.12 (CH_2Ph), 50.82 (CH_2Ph), 79.65 (*t*Bu-C), 79.78 (*t*Bu-C), 127.21 (C-4), 127.27 (*o*-Ph-CH), 127.92 (*p*-Ph-CH), 128.11 (C-3), 128.62 (*m*-Ph-CH), 138.67 (Ph-C), 138.94 (Ph-C), 155.75 (Boc CO), 156.26 (Boc CO) ppm—MS (EI, 70 eV): m/z (%) = 221.2/220.2 [$\text{M}-\text{C}_4\text{H}_7$] $^{+}$ (4/29), 165.1/164.1 [$\text{M}-\text{C}_8\text{H}_{15}$] $^{+}$ (3/25), 121.1/120.1 [$\text{C}_8\text{H}_{10}\text{N}$] $^{+}$ (6/64), 92.1/91.1 [Bn] $^{+}$ (9/100)—HRMS (ESI) calcd. [$\text{M}+\text{Na}$] $^{+}$ 298.17775; found 298.17775.

tert-Butyl 4-Azidopentyl(benzyl)carbamate (**8**). NaN_3 (1.586 g, 24.40 mmol) was added to a solution of the bromine derivative **5** (2.873 g, 8.06 mmol) in DMF (dry, 25 mL) and stirred at 25°C under nitrogen atmosphere for 3 hours. DMF was removed azeotropically with toluene under reduced pressure. The residue was suspended in dichloromethane, filtered through Celite, and concentrated. Purification with flash column chromatography on silica gel (DCM 100%) gave compound **8** (2.498 g, 97%) as colorless oil. IR (ATR-FTIR): $\tilde{\nu}$ = 2973 (w), 2930 (w), 2359 (w), 2341 (w), 2097 (m), 1688 (s), 1495 (w), 1454 (m), 1413 (m), 1390 (w), 1380 (w), 1364 (m), 1241 (m), 1165 (s), 1138 (s), 1073 (w), 1028 (w), 966 (w), 875 (m), 802 (w), 768 (w), 733 (m), 699 (m), 669 (w), 647 (w), 630 (w), 620 (w) cm^{-1} — ^1H -NMR (600 MHz, CDCl_3): δ = 1.20 (d, $^3J_{\text{H-H}}$ = 6.54 Hz, 3 H, Me), 1.42–1.60 (m, 13 H, *t*Bu-Me, 2- CH_2 , 3- CH_2), 3.11–3.20 (m, 2 H, 1- CH_2), 3.37–3.40 (m, 1 H, 4-H), 4.39–4.42 (m, 2 H, CH_2Ph), 7.20–7.25 (m, 3 H, *o*-Ph-H, *p*-Ph-H), 7.29–7.31 (m, 2 H, *m*-Ph-H) ppm— ^{13}C -NMR (150 MHz, CDCl_3): δ = 19.65 (Me), 24.60 (C-2), 24.89 (C-2), 28.63 (*t*Bu-Me), 33.52 (C-3), 46.20 (C-1), 50.04 (CH_2Ph),

50.57 (CH_2Ph), 57.85 (C-4), 79.96 (*t*Bu-C), 127.37 (*o*-Ph-CH), 127.92 (*p*-Ph-CH), 128.69 (*m*-Ph-CH), 138.54 (Ph-C), 138.72 (Ph-C), 155.85 (Boc CO), 156.20 (Boc CO) ppm—MS (EI, 70 eV): m/z (%) = 218.2/217.2 [$\text{M}-\text{C}_5\text{H}_9\text{O}_2$] $^{+}$ (1/7), 92.1/91.1 [C_7H_7] $^{+}$ (7/80), 57.1 (100)—HRMS (ESI) calcd. [$\text{M}+\text{Na}$] $^{+}$ 341.19480; found 341.19478.

4-Azido-*N*-benzylpentan-1-amine (**9**). TFA (921.0 mg, 8.08 mmol, and 600 μL) was added to a solution of azide **8** (51.4 mg, 0.16 mmol) in DCM (1.5 mL) at 25°C and the reaction mixture was stirred for 30 min at 25°C. The mixture was carefully alkalised using aqueous NaOH solution and was exhaustively extracted with dichloromethane. The combined organic extracts were dried (MgSO_4), filtered, and concentrated. Purification with flash column chromatography on deactivated silica gel (DCM/MeOH 50:1) gave **9** (33.6 mg, 96%) as colorless oil. IR (ATR-FTIR): $\tilde{\nu}$ = 3085 (w), 3062 (w), 3026 (w), 2972 (w), 2931 (w), 2860 (w), 2813 (w), 2358 (w), 2343 (w), 2094 (s), 1603 (w), 1494 (w), 1453 (m), 1379 (w), 1326 (w), 1244 (m), 1188 (w), 1116 (m), 1074 (w), 1027 (w), 968 (w), 908 (w), 805 (w), 731 (s), 697 (s), 670 (w), 653 (w), 622 (w), 610 (w), 600 (w) cm^{-1} — ^1H -NMR (600 MHz, CDCl_3): δ = 1.23 (d, $^3J_{\text{H-H}}$ = 6.60 Hz, 3 H, Me), 1.46–1.57 (m, 3 H, 2-H, 3- CH_2), 1.58–1.65 (m, 1 H, 2-H), 1.70 (s, br, 1 H, NH), 2.63 (t, $^3J_{\text{H-H}}$ = 6.90 Hz, 2 H, 1- CH_2), 3.39–3.45 (m, 1 H, 4-H), 3.77 (s, 2 H, CH_2Ph), 7.22–7.25 (m, 1 H, *p*-Ph-H), 7.30–7.31 (m, 4 H, *o*-Ph-H, *m*-Ph-H) ppm— ^{13}C -NMR (150 MHz, CDCl_3): δ = 19.67 (Me), 26.72 (C-2), 34.11 (C-3), 49.07 (C-1), 54.10 (CH_2Ph), 58.08 (C-4), 127.22 (*p*-Ph-CH), 128.37 (Ph-CH), 128.64 (Ph-CH), 140.26 (Ph-C) ppm—MS (EI, 70 eV): m/z (%) = 218.1/217.1 [$\text{M}-\text{H}$] $^{+}$ (2/16), 92.1/91.1 [C_7H_7] $^{+}$ (9/100)—HRMS (ESI) calcd. [$\text{M}+\text{H}$] $^{+}$ 219.16042; found 219.16042.

tert-Butyl 4-Aminopentyl(benzyl)carbamate (**10**). NaN_3 (26.8 mg, 0.41 mmol) and PPh_3 (102.6 mg, 0.39 mmol) were added to a solution of the bromine derivative **5** (42.2 mg, 0.12 mmol) in DMF (dry, 1 mL) at 25°C under nitrogen atmosphere. The reaction mixture was stirred for 2.5 hours until the conversion of **5** to the corresponding amine and iminophosphorane (thin-layer chromatography on silica gel and eluting with petroleum ether/EtOAc 5:1, followed by deactivation of the silica gel by gaseous ammonia using DCM/MeOH 10:1). For the hydrolysis of the iminophosphorane, KOH (39.3 mg, 0.70 mmol) was added and stirred at 25°C for 16 hours. Water was added and the aqueous phase was exhaustively extracted using dichloromethane. The combined organic extracts were dried (MgSO_4), filtered, and concentrated. DMF residues were removed using high vacuum. Purification with flash column chromatography on basic alumina (activity level V, DCM/MeOH 30:1) gave compound **10** (25.2 mg, 75%) as colorless oil. IR (ATR-FTIR): $\tilde{\nu}$ = 2971 (w), 2926 (w), 1685 (s), 1604 (w), 1495 (w), 1453 (m), 1413 (m), 1390 (m), 1364 (m), 1241 (m), 1164 (s), 1143 (s), 1091 (m), 1074 (w), 1028 (w), 1002 (w), 966 (w), 882 (m), 812 (w), 769 (w), 731 (m), 699 (m), 672 (w), 638 (w), 620 (w), 606 (w) cm^{-1} — ^1H -NMR (600 MHz, CDCl_3): δ = 1.03 (d, $^3J_{\text{H-H}}$ = 5.76 Hz, 3 H, Me), 1.27 (m, 2H, 3- CH_2), 1.40–1.47 (m, 11 H, *t*Bu-Me, 2- CH_2), 2.04 (m, 2 H, NH_2), 2.84–2.88 (m, 1 H, 4-H),

3.09–3.20 (m, 2 H, 1-CH₂), 4.38–4.42 (d, $^2J_{\text{H-H}} = 25.80$ Hz, 2 H, CH₂Ph), 7.19–7.24 (m, 3 H, *o*-Ph-CH, *p*-Ph-CH), 7.28–7.30 (m, 2 H, *m*-Ph-CH) ppm—¹³C-NMR (150 MHz, CDCl₃): δ = 23.69 (Me), 24.85 (C-2), 25.20 (C-2), 28.64 (*t*Bu-Me), 36.77 (C-3), 37.01 (C-3), 46.64 (C-1), 46.76 (C-1), 46.94 (C-4), 47.03 (C-4), 50.05 (CH₂Ph), 50.71 (CH₂Ph), 79.80 (*t*Bu-C), 79.91 (*t*Bu-C), 127.31 (*o*-Ph-CH), 127.91 (*p*-Ph-CH), 128.66 (*m*-Ph-CH), 138.67 (Ph-C), 138.85 (Ph-C), 155.85 (Boc CO) ppm—MS (EI, 70 eV): m/z (%) = 293.3/292.3 [M]⁺ (3/12), 237.2/236.2 [M-C₄H₈]⁺ (3/18), 192.2/191.2 [M-C₅H₉O₂]⁺ (6/16), 92.1/91.1 [C₇H₇]⁺ (10/100)—HRMS (ESI) calcd. [M+H]⁺ 293.22235; found 293.22235.

The intermediary iminophosphorane compound (not displayed) was obtained in experiments without a KOH hydrolysis in various amounts as colorless solid. Mp 63°C (DCM/MeOH)—IR (ATR-FTIR): $\tilde{\nu}$ = 3054 (w), 2975 (w), 2964 (w), 2817 (w), 2717 (w), 2359 (w), 2342 (w), 1682 (s), 1588 (w), 1454 (w), 1436 (m), 1415 (m), 1364 (w), 1310 (w), 1268 (m), 1245 (m), 1222 (w), 1165 (s), 1135 (s), 1112 (s), 1058 (w), 1027 (w), 997 (w), 968 (w), 876 (w), 813 (w), 723 (s), 692 (s), 617 (w) cm⁻¹—¹H-NMR (600 MHz, CDCl₃): δ = 1.28–1.32 (m, br, 6 H, Me), 1.35–1.41 (m, 22 H, *t*Bu-Me, 2-CH₂), 1.45–1.66 (m, br, 4 H, 3-CH₂), 2.77–2.88 (m, 2 H, 4-H), 2.91–3.06 (m, 4 H, 1-CH₂), 4.24–4.39 (m, 4 H, CH₂Ph), 7.12–7.13 (m, 4 H, Ph-H), 7.18–7.20 (m, 2 H, *p*-Ph-H), 7.23–7.27 (m, 4 H, Ph-H), 7.56–7.59 (m, 12 H, Ph-H), 7.68–7.70 (m, 6 H, *p*-Ph-H), 7.80–7.83 (m, 12 H, Ph-H) ppm—¹³C-NMR (150 MHz, CDCl₃): δ = 22.91 (Me), 22.93 (Me), 25.03 (C-2), 25.64 (C-2), 28.54 (*t*Bu-Me), 28.63 (*t*Bu-Me), 35.26 (C-3), 35.30 (C-3), 35.43 (C-3), 35.47 (C-3), 46.27 (C-1), 46.46 (C-1), 49.93 (CH₂Ph), 50.68 (C-4), 50.72 (CH₂Ph), 50.95 (C-4), 79.74 (*t*Bu-C), 79.79 (*t*Bu-C), 122.16 (P-Ph-C), 122.85 (P-Ph-C), 127.16 (Ph-CH), 127.25 (Ph-CH), 127.30 (Ph-CH), 127.71 (Ph-CH), 128.55 (Ph-CH), 128.61 (Ph-CH), 129.83 (P-Ph-CH), 129.92 (P-Ph-CH), 133.83 (P-Ph-CH), 133.91 (P-Ph-CH), 134.64 (P-*p*-Ph-CH), 134.68 (P-*p*-Ph-CH), 138.46 (Ph-C), 138.80 (Ph-C), 155.70 (Boc CO), 156.13 (Boc CO) ppm—³¹P-NMR: (160 MHz, CDCl₃): 35.94 ppm—MS (EI, 70 eV): m/z (%) = 537.2 [M-Me]⁺ (4), 362.2/361.2 [M-Bn-Boc]⁺ (1/4), 306.1/305.1/304.1 [Ph₃PNC₂H₄]⁺ (3/24/100), 263.1/262.1 [PPH₃]⁺ (8/38), 92.1/91.1 [C₇H₇]⁺ (2/17)—HRMS (ESI) calcd. [M+H]⁺ 553.29784; found 553.29784.

tert-Butyl Benzyl(4'-(7'-chloroquinolin-4'-ylamino)pentyl)carbamate (**II**). To a solution of 4,7-dichloroquinoline (330.4 mg, 1.67 mmol) in 1,4-dioxane (dry, 8 mL), a 10 min stirred suspension of Pd₂(dba)₃ (37.5 mg, 0.04 mmol) and (±)-BINAP (54.7 mg, 0.09 mmol) in 1,4-dioxane (dry, 2 mL) was added at 25°C under nitrogen atmosphere, followed by the amine **10** (730.2 mg, 2.50 mmol) and KO^tBu (373.2 mg, 3.33 mmol). The reaction mixture was stirred at 85°C for 4 hours; after allowing cooling down to 25°C, the mixture was filtered and concentrated. Purification with flash column chromatography on silica gel (petroleum ether/EtOAc 3:1) and recrystallization (diethyl ether/petroleum ether) gave **II** (477.7 mg, 63%) as colorless crystals. Mp 104°C (diethyl ether/petroleum ether)—IR (ATR-FTIR): $\tilde{\nu}$ = 3734 (w), 3628 (w), 3595 (w), 3227 (w), 3064 (w), 3007 (w), 2964 (w), 2920 (w), 2360 (m), 2341 (m), 1679 (s), 1611 (w), 1572 (s),

1549 (m), 1494 (w), 1465 (m), 1451 (m), 1432 (m), 1417 (m), 1395 (w), 1362 (m), 1329 (m), 1315 (m), 1273 (m), 1245 (m), 1214 (m), 1165 (m), 1152 (s), 1133 (s), 1104 (w), 1084 (m), 1067 (w), 1031 (w), 1001 (w), 967 (w), 943 (w), 911 (w), 872 (m), 851 (m), 835 (m), 818 (m), 767 (m), 732 (m), 694 (m), 669 (w), 647 (m), 623 (w), 602 (m) cm⁻¹—¹H-NMR (600 MHz, CDCl₃): δ = 1.25 (d, $^3J_{\text{H-H}} = 6.36$ Hz, 3 H, Me), 1.44 (s, 9 H, *t*Bu-Me), 1.50–1.64 (m, 4 H, 2-CH₂, 3-CH₂), 3.14 (m, br, 1 H, 1-CH₂), 3.41–3.45 (m, br, 1 H, 1-CH₂), 3.68 (m, br, 1 H, 4-H), 4.30–4.43 (m, 2 H, CH₂Ph), 5.71 (s, br, NH), 6.35 (m, br, 1 H, 3'-H), 7.17–7.28 (m, 5 H, *o*-Ph-H, *m*-Ph-H, *p*-Ph-H), 7.32 (dd, $^3J_{\text{H-H}} = 8.88$ Hz, $^4J_{\text{H-H}} = 1.92$ Hz, 1 H, 6'-H), 7.87 (m, br, 1 H, 5'-H), 7.94 (d, $^4J_{\text{H-H}} = 1.50$ Hz, 1 H, 8'-H), 8.45 (m, br, 1 H, 2'-H) ppm—¹³C-NMR (150 MHz, CDCl₃): δ = 20.74 (Me), 25.06 (CH₂), 25.25 (CH₂), 28.63 (*t*Bu-Me), 32.83 (CH₂), 46.48 (C-1), 48.21 (C-4), 49.24 (C-4), 50.79 (CH₂Ph), 80.00 (*t*Bu-C), 80.38 (*t*Bu-C), 99.15 (C-3'), 117.45 (C-4'a), 122.06 (C-5'), 125.43 (C-6'), 127.23 (*o*-Ph-C), 127.46 (*p*-Ph-C), 127.93 (C-8'), 128.25 (C-8'), 128.71 (*m*-Ph-C), 135.29 (C-7'), 138.53 (Ph-C), 148.78 (C-8'a), 148.98 (C-8'a), 149.82 (C-4'), 151.38 (C-2'), 152.01 (C-2'), 156.35 (Boc CO) ppm—MS (EI, 70 eV): m/z (%) = 455.2/454.2/453.2 [M]⁺ (19/17/49), 398.1/397.1/396.1 [M-C₄H₉]⁺ (6/7/13), 221.0/220.0/219.0 [C₁₂H₁₂ClN₂]⁺ (11/7/34), 207.0/206.0/205.0 [C₁₁H₁₀ClN₂]⁺ (35/26/100), 92.0/91.0 [C₇H₇]⁺ (9/91)—HRMS (ESI) calcd. [M+H]⁺ 454.22558; found 454.22559.

*N*¹-Benzyl-*N*⁴-(7'-chloroquinolin-4'-yl)pentane-1,4-diamine (**12**). TFA (1.432 g, 12.56 mmol, and 933 μ L) was added to a solution of the Boc protected **II** (114.1 mg, 0.25 mmol) in DCM (15 mL) and the reaction mixture was stirred at 25°C for 1.5 hours. The mixture was carefully alkalised with aqueous NaOH solution and was exhaustively extracted with dichloromethane. The combined organic extracts were dried (MgSO₄), filtered, and concentrated. Purification with flash column chromatography on deactivated silica gel (DCM/MeOH 30:1) and recrystallization (DCM/diethyl ether/petroleum ether) gave **12** (77.5 mg, 88%) as light beige solid. Mp 88°C (DCM/diethyl ether/petroleum ether)—IR (ATR-FTIR): $\tilde{\nu}$ = 3247 (w), 3062 (w), 3027 (w), 2958 (w), 2861 (w), 2815 (w), 2790 (w), 2360 (w), 2337 (w), 1610 (w), 1569 (s), 1542 (m), 1490 (w), 1452 (m), 1425 (m), 1369 (m), 1328 (m), 1280 (w), 1251 (m), 1201 (w), 1137 (m), 1106 (m), 1078 (m), 1041 (w), 1008 (w), 956 (w), 902 (m), 867 (m), 848 (m), 817 (m), 792 (m), 738 (m), 698 (s), 638 (m) cm⁻¹—¹H-NMR (600 MHz, MeOD-d₄): δ = 1.30 (d, $^3J_{\text{H-H}} = 6.42$ Hz, 3 H, Me), 1.60–1.66 (m, 3 H, 2-CH₂, 3-H), 1.70–1.75 (m, 2 H, 3-CH₂), 2.59 (t, $^3J_{\text{H-H}} = 7.08$ Hz, 2 H, 1-CH₂), 3.70 (s, 2 H, CH₂Ph), 3.76–3.78 (m, 1 H, 4-H), 6.50 (d, $^3J_{\text{H-H}} = 5.76$ Hz, 1 H, 3'-H), 7.20–7.23 (m, 1 H, *p*-Ph-H), 7.27–7.28 (m, 4 H, *o*-Ph-H, *m*-Ph-H), 7.37 (dd, $^3J_{\text{H-H}} = 9.03$ Hz, $^4J_{\text{H-H}} = 2.19$, 1 H, 6'-H), 7.76 (d, $^4J_{\text{H-H}} = 2.10$ Hz, 1 H, 8'-H), 8.16 (d, $^3J_{\text{H-H}} = 9.00$ Hz, 1 H, 5'-H), 8.31 (d, $^3J_{\text{H-H}} = 5.64$ Hz, 2'-H) ppm—¹³C-NMR (150 MHz, MeOD-d₄): δ = 20.50 (Me), 27.30 (C-2), 35.02 (C-3), 49.58 (C-4), 49.78 (C-1), 54.55 (CH₂Ph), 99.97 (C-3'), 118.98 (C-4'a), 124.62 (C-5'), 125.96 (C-6'), 127.71 (C-8'), 128.30 (*p*-Ph-CH), 129.58 (Ph-CH), 129.66 (Ph-CH), 136.43 (C-7'), 140.71 (Ph-C), 150.04 (C-8'a),

152.28 (C-2'), 152.58 (C-4') ppm—MS (EI, 70 eV): m/z (%) = 354.2/353.2 [M]⁺⁺ (6/12), 264.1/263.1/262.1 [M-Bn]⁺ (10/7/29), 234.0/233.0 [C₁₃H₁₄ClN₂]⁺ (7/9), 221.1/220.1/219.1 [C₁₁H₁₂ClN₂]⁺ (7/5/22), 207.0/206.0/205.0 [C₁₁H₁₀ClN₂]⁺ (13/20/33), 178.0 [C₉H₇ClN₂]⁺ (12), 91.1 [Bn]⁺ (100)—HRMS (ESI) calcd. 354.17315 [M+H]⁺; found 354.17307.

tert-Butyl 4-(7'-Chloroquinolin-4'-ylamino)butylcarbamate (**14**). Boc₂O (199.5 mg, 0.91 mmol, and 210 μ L) was added to a solution of **13** [37] (203.0 mg, 0.81 mmol) in MeCN (dry, 6 mL) at 0°C under nitrogen atmosphere, and the reaction mixture was stirred for 1 hour at 25°C and concentrated. The residue was suspended in water and alkalized with aqueous NaOH solution and the mixture was exhaustively extracted with dichloromethane. The combined organic extracts were dried (MgSO₄), filtered, and concentrated. Purification with flash column chromatography on deactivated silica gel (DCM/MeOH 40:1) and recrystallization (CHCl₃/petroleum ether) yielded in compound **14** (258.9 mg, 91%) as beige crystals. Mp 176°C (CHCl₃/petroleum ether)—IR (ATR-FTIR): $\tilde{\nu}$ = 3344 (w), 3181 (w), 3003 (w), 2982 (w), 2961 (w), 2930 (w), 2864 (w), 2360 (w), 2341 (w), 1677 (s), 1610 (w), 1578 (s), 1541 (s), 1487 (w), 1468 (w), 1449 (m), 1427 (m), 1389 (w), 1365 (m), 1354 (m), 1330 (m), 1306 (w), 1286 (s), 1274 (s), 1249 (m), 1234 (m), 1162 (s), 1141 (s), 1124 (s), 1081 (w), 1036 (w), 1021 (w), 994 (m), 951 (m), 895 (w), 884 (m), 852 (m), 828 (w), 818 (s), 770 (m), 751 (m), 715 (w), 668 (w), 643 (m), 624 (w) cm⁻¹—¹H-NMR (600 MHz, MeOD-d₄): δ = 1.42 (s, 9 H, *t*Bu-Me), 1.59–1.64 (m, 2 H, 2-CH₂), 1.73–1.78 (m, 2 H, 3-CH₂), 3.11 (t, ³J_{H-H} = 6.90 Hz, 2 H, 1-CH₂), 3.38 (t, ³J_{H-H} = 7.11 Hz, 2 H, 4-CH₂), 6.53 (d, ³J_{H-H} = 5.76 Hz, 1 H, 3'-H), 7.39 (dd, ³J_{H-H} = 8.97 Hz, ⁴J_{H-H} = 2.13 Hz, 1 H, 6'-H), 7.77 (d, ⁴J_{H-H} = 1.98 Hz, 1 H, 8'-H), 8.11 (d, ³J_{H-H} = 8.94 Hz, 1 H, 5'-H), 8.34 (d, ³J_{H-H} = 5.64 Hz, 1 H, 2'-H) ppm—¹³C-NMR (150 MHz, MeOD-d₄): δ = 26.66 (C-3), 28.78 (C-2), 28.92 (*t*Bu-Me), 41.10 (C-1), 43.81 (C-4), 80.06 (*t*Bu-C), 99.79 (C-3'), 118.91 (C-4'a), 124.54 (C-5'), 126.10 (C-6'), 127.60 (C-8'), 136.49 (C-7'), 149.72 (C-8'a), 152.45 (C-2'), 152.95 (C-4'), 158.81 (Boc CO) ppm—MS (EI, 70 eV): m/z (%) = 351.0/350.1/349.1 [M]⁺⁺ (12/8/33), 295.0/294.0/293.0 [M-C₄H₉]⁺⁺ (7/6/22), 251.0/250.0/249.0 [M-C₅H₈O₂]⁺⁺ (2/2/6), 193.0/192.0/191.0 [C₁₀H₈ClN₂]⁺ (34/21/100), 180.0/179.0/178.0 [C₉H₇ClN₂]⁺⁺ (10/32/19)—HRMS (ESI) calcd. [M+H]⁺ 350.16298; found 350.16297.

tert-Butyl Benzyl(4-(benzyl(7'-chloroquinolin-4'-yl)amino)butyl)carbamate (**15**). NaH (51.4 mg of a 55% oily dispersion, 1.18 mmol) was added to a solution of the Boc protected **14** (134.8 mg, 0.39 mmol) in DMF (dry, 2 mL) under nitrogen atmosphere at 0°C and the reaction mixture was stirred for 30 min. Benzyl bromide (50.4 μ L, 72.5 mg, and 0.42 mmol) was added at 0°C, and the mixture was allowed to warm up to 25°C and was stirred for further 6 hours. DMF was removed using high vacuum and the residue was purified with flash column chromatography on silica gel (petroleum ether/EtOAc 2:1) to give compounds **15** (47.2 mg, 23%) and **16** (9.1 mg, 23%) both as highly viscous colorless oil. Compound **15**: IR (ATR-FTIR): $\tilde{\nu}$ = 3062 (w), 3027 (w), 2971 (w), 2931 (w),

2861 (w), 2360 (w), 1687 (s), 1604 (w), 1565 (s), 1494 (m), 1454 (m), 1417 (s), 1363 (s), 1295 (m), 1240 (m), 1162 (s), 1139 (s), 1074 (m), 1051 (w), 1029 (w) cm⁻¹—¹H-NMR (600 MHz, MeOD-d₄): δ = 1.36 (s, 9 H, *t*Bu-Me), 1.41–1.43 (m, 2 H, 2-CH₂), 1.51–1.55 (m, 2 H, 3-CH₂), 3.08–3.15 (m, 2 H, 1-CH₂), 3.25 (m, 2 H, 4-CH₂), 4.28–4.31 (m, 2 H, CH₂Ph), 4.51 (s, br, 2 H, CH₂Ph), 6.90 (d, ³J_{H-H} = 5.28 Hz, 1 H, 3'-H), 7.11–7.12 (m, 2 H, Ph-CH), 7.16–7.19 (m, 1 H, Ph-CH), 7.21–7.29 (m, 7 H, Ph-CH), 7.44 (d, ³J_{H-H} = 8.58 Hz, 1 H, 6'-H), 7.92 (s, 1 H, 8'-H), 8.11 (d, ³J_{H-H} = 8.94 Hz, 1 H, 5'-H), 8.51 (s, br, 1 H, 2'-H) ppm—¹³C-NMR (150 MHz, MeOD-d₄): δ = 25.13 (C-3), 25.25 (C-3), 26.62 (C-2), 27.15 (C-2), 28.80 (*t*Bu-Me), 47.92 (C-1), 51.30 (CH₂Ph), 51.89 (CH₂Ph), 53.00 (C-4), 53.26 (C-4), 58.35 (CH₂Ph), 58.73 (CH₂Ph), 123.91 (C-4'a), 127.17 (C-6'), 127.41 (C-5'), 128.29 (Ph-CH), 128.39 (Ph-CH), 128.52 (C-8'), 129.10 (Ph-CH), 129.64 (Ph-CH), 129.79 (Ph-CH), 136.58 (C-7'), 138.75 (Ph-C), 139.76 (Ph-C), 140.02 (Ph-C), 151.14 (C-8'a), 152.22 (C-2'), 157.53 (Boc CO), 157.80 (Boc CO), 158.06 (C-4') ppm—MS (EI, 70 eV): m/z (%) = 531.0/530.0/529.0 [M]⁺⁺ (8/8/18), 474.0/473.0/472.0 [M-C₄H₉]⁺ (3/2/6), 440.0/439.0/438.0 [M-Bn]⁺ (6/5/16), 91 [Bn]⁺ (100)—HRMS (ESI) calcd. [M+H]⁺ 530.25688; found 530.25689.

tert-Butyl 4-(Benzyl(7'-chloroquinolin-4'-yl)amino)butylcarbamate (**16**). IR (ATR-FTIR): $\tilde{\nu}$ = 3241 (w, br), 3031 (w), 2973 (w), 2931 (w), 2863 (w), 1693 (s), 1604 (m), 1565 (s), 1496 (s), 1452 (m), 1425 (s), 1388 (m), 1363 (s), 1292 (s), 1272 (s), 1247 (s), 1164 (s), 1076 (m), 1045 (m), 997 (m) cm⁻¹—¹H-NMR (600 MHz, MeOD-d₄): δ = 1.38 (s, 9 H, *t*Bu-Me), 1.40–1.45 (m, 2 H, 2-CH₂), 1.65–1.70 (m, 2 H, 3-CH₂), 2.98 (t, ³J_{H-H} = 6.75 Hz, 2 H, 1-CH₂), 3.31–3.34 (m, 2 H, 4-CH₂), 4.58 (s, 2 H, CH₂Ph), 6.95 (d, ³J_{H-H} = 5.34 Hz, 1 H, 3'-H), 7.22–7.24 (m, 1 H, *p*-Ph-H), 7.27–7.30 (m, 4 H, *o*-Ph-H, *m*-Ph-H), 7.46 (dd, ³J_{H-H} = 9.06 Hz, ⁴J_{H-H} = 1.98 Hz, 1 H, 6'-H), 7.91 (d, ⁴J_{H-H} = 1.92 Hz, 1 H, 8'-H), 8.16 (d, ³J_{H-H} = 9.06 Hz, 1 H, 5'-H), 8.51 (d, ³J_{H-H} = 5.22 Hz, 1 H, 2'-H) ppm—¹³C-NMR (150 MHz, MeOD-d₄): δ = 25.18 (C-3), 28.60 (C-2), 28.92 (*t*Bu-Me), 41.05 (C-1), 53.43 (C-4), 58.34 (CH₂Ph), 79.98 (*t*Bu-C), 112.19 (C-3'), 123.87 (C-4'a), 127.09 (C-6'), 127.48 (C-5'), 128.44 (C-8'), 128.66 (*p*-Ph-CH), 129.07 (*o*-Ph-CH), 129.77 (*m*-Ph-CH), 136.55 (C-7'), 138.80 (Ph-C), 151.13 (C-8'a), 152.19 (C-2'), 158.15 (C-4'), 158.67 (Boc CO) ppm—MS (EI, 70 eV): m/z (%) = 441.0/440.0/439.0 [M]⁺⁺ (3/3/7), 91 [Bn]⁺ (100)—HRMS (ESI) calcd. [M+H]⁺ 440.20993; found 440.20993.

tert-Butyl 4-(6'-Methoxyquinolin-8'-ylamino)pentylcarbamate (**27**). Boc₂O (2.755 g, 12.6 mmol, and 2.9 mL) was added to a solution of the free base of the commercially available primaquine biphosphate (1.605 g, 6.19 mmol) in DCM (dry, 40 mL) at 0°C and the reaction mixture was stirred for 1 hour at 25°C. The organic layer was washed with aqueous NaHCO₃ solution, dried (MgSO₄), and concentrated. Purification with flash column chromatography on deactivated silica gel (petroleum ether/EtOAc 5:1) gave compound **27** (2.081, 94%) as yellow oil. IR (ATR-FTIR): $\tilde{\nu}$ = 3380 (w, br), 2965 (w), 2931 (w), 2867 (w), 2501 (w), 2360 (w), 2339 (w), 1691 (s), 1612 (m), 1577 (m), 1515 (s), 1452 (m), 1405 (s), 1386

(s), 1365 (m), 1338 (m), 1245 (m), 1209 (s), 1160 (s), 1074 (s), 1035 (m), (970), 865 (w), 815 (m), 786 (m), 663 (m), 622 (m) cm^{-1} — ^1H -NMR (600 MHz, MeOD-d_4): δ = 1.25 (d, $^3J_{\text{H-H}}$ = 6.36 Hz, 3 H, Me), 1.40 (s, 9 H, *t*Bu-Me), 1.54–1.68 (m, 4 H, 2-H, 3-H), 3.02–3.06 (m, 2 H, 1-H), 3.59–3.62 (m, 1 H, 4-H), 3.85 (s, 3 H, OMe), 6.30 (s, 1 H, 7'-H), 6.42 (d, $^4J_{\text{H-H}}$ = 2.40 Hz, 1 H, 5'-H), 7.32 (dd, $^3J_{\text{H-H}}$ = 4.20 Hz, 8.22 Hz, 1 H, 3'-H), 7.99 (d, $^3J_{\text{H-H}}$ = 8.28 Hz, $^4J_{\text{H-H}}$ = 1.56 Hz, 1 H, 4'-H), 8.47 (dd, $^3J_{\text{H-H}}$ = 4.20 Hz, $^4J_{\text{H-H}}$ = 1.56 Hz, 1 H, 2'-H) ppm— ^{13}C -NMR (150 MHz, MeOD-d_4): δ = 20.86 (Me), 27.74 (C-2), 28.91 (*t*Bu-Me), 35.00 (C-3), 41.47 (C-1), 49.10 (C-4), 55.77 (OMe), 79.95 (*t*Bu-C), 93.18 (C-5'), 98.59 (C-7'), 123.01 (C-3'), 131.65 (C-4'a), 136.43 (C-4'), 136.56 (C-8'a), 145.40 (C-2'), 146.22 (C-8'), 158.66 (Boc-CO), 161.06 (C-6') ppm—MS (EI, 70 eV): m/z (%) = 361.2/360.2/359.2 [$\text{M}]^{++}$ (3/9/9), 260.2/259.2 [$\text{M-C}_5\text{H}_8\text{O}_2$] $^{++}$ (5/5), 203.1/202.1/201.1 [$\text{C}_{12}\text{H}_{13}\text{N}_2\text{O}]^+$ (16/68/100)—HRMS (ESI) calcd. [$\text{M}+\text{Na}]^+$ 382.21011; found 382.21011.

tert-Butyl Benzyl(4-(6'-methoxyquinolin-8'-ylamino)pentyl) carbamate (**28**). NaH (23.6 mg of a 55% oily dispersion, 0.25 mmol) was added at 0°C under nitrogen atmosphere to a solution of Boc protected **27** (69.5 mg, 0.19 mmol) in DMF (dry, 2 mL) and the reaction mixture was stirred for 30 min at 0°C. At 25°C benzyl bromide (25.3 μL , 36.4 mg, and 0.22 mmol) was added and the mixture was stirred for further 1.5 hours. DMF was removed using high vacuum and the residue was purified with flash column chromatography on silica gel (petroleum ether/EtOAc 8:1) to give compound **28** (67.5 mg, 79%) as yellow oil. IR (ATR-FTIR): $\tilde{\nu}$ = 3384 (w, br), 2965 (w), 2929 (w), 2360 (w), 2337 (w), 2086 (w, br), 1862 (w, br), 1687 (s), 1614 (m), 1575 (m), 1517 (s), 1454 (s), 1415 (s), 1386 (s), 1365 (m), 1241 (m), 1213 (m), 1159 (s), 1087 (w), 1051 (m), 1029 (w) cm^{-1} — ^1H -NMR (600 MHz, MeOD-d_4): δ = 1.23–1.24 (m, 6 H, Me), 1.39 (d, $^4J_{\text{H-H}}$ = 16.26 Hz, 18 H, *t*Bu-Me), 1.56–1.58 (m, 4 H, CH_2), 1.59–1.62 (m, 4 H, CH_2), 3.14–3.15 (m, 2 H, 1-H), 3.19–3.28 (m, 2 H, 1-H), 3.58–3.60 (m, 2 H, 4-H), 3.86 (s, 6 H, OMe), 4.29–4.40 (m, 4 H, CH_2Ph), 6.28 (d, $^3J_{\text{H-H}}$ = 12.78 Hz, 2 H, 7'-H), 6.46 (d, $^3J_{\text{H-H}}$ = 2.40 Hz, 2 H, 5'-H), 7.13–7.20 (m, 6 H, Ph-H), 7.24–7.26 (m, 4 H, Ph-H), 7.37 (dd, $^3J_{\text{H-H}}$ = 4.23 Hz, 8.19 Hz, 2 H, 3'-H), 8.04 (dd, $^3J_{\text{H-H}}$ = 8.28 Hz, $^4J_{\text{H-H}}$ = 1.44 Hz, 2 H, 4'-H), 8.49 (dd, $^3J_{\text{H-H}}$ = 4.20 Hz, $^4J_{\text{H-H}}$ = 1.56 Hz, 2 H, 2'-H) ppm— ^{13}C -NMR (150 MHz, MeOD-d_4): δ = 20.90 (Me), 20.99 (Me), 25.45 (CH_2), 25.78 (CH_2), 28.74 (*t*Bu-Me), 34.56 (CH_2), 34.65 (CH_2), 47.85 (C-1), 48.07 (C-1), 48.70 (C-4), 51.06 (CH_2Ph), 51.55 (CH_2Ph), 55.75 (OMe), 81.30 (*t*Bu-C), 81.38 (*t*Bu-C), 93.01 (C-5'), 98.61 (C-7'), 123.12 (C-3'), 128.34 (Ph-CH), 128.39 (Ph-CH), 128.44 (Ph-CH), 128.77 (Ph-CH), 129.64 (Ph-CH), 129.70 (Ph-CH), 131.79 (C-4'a), 136.53 (C-4'), 136.57 (C-8'a), 139.68 (Ph-C), 139.98 (Ph-C), 145.45 (C-2'), 146.22 (C-8'), 157.78 (Boc CO), 157.94 (Boc CO), 161.11 (C-6') ppm—MS (EI, 70 eV): m/z (%) = 451.3/450.3/449.3 [$\text{M}]^{++}$ (2/11/35), 203.1/202.1/201.1 [$\text{C}_{12}\text{H}_{13}\text{N}_2\text{O}]^+$ (1/15/100), 174.1 [$\text{C}_{10}\text{H}_{10}\text{N}_2\text{O}]^{++}$ (29), 160.1 [$\text{C}_9\text{H}_8\text{N}_2\text{O}]^{++}$ (10), 92.1/91.1 [C_7H_7] $^+$ (2/17)—HRMS (ESI) calcd. [$\text{M}+\text{H}]^+$ 450.27512; found 450.27512.

tert-Butyl Benzyl(4-(1',3'-dioxoisindolin-2'-yl)pentyl)carbamate (**30**). Potassium phthalimide (180.0 mg, 1.03 mmol) was added to a solution of the bromine derivative **5** (168.5 mg, 0.47 mmol) in DMF (dry, 5 mL) and the reaction mixture was stirred at 25°C for 72 hours. DMF was removed azeotropically with toluene under reduced pressure, and the residue was suspended in aqueous NaHCO_3 solution and exhaustively extracted with dichloromethane. Purification with flash column chromatography on silica gel (petroleum ether/EtOAc 10:1) gave compound **30** (161.5 mg, 81%) as viscous colorless oil. IR (ATR-FTIR): $\tilde{\nu}$ = 2973 (w), 2931 (w), 1773 (w), 1703 (s), 1687 (s), 1612 (w), 1495 (w), 1466 (w), 1453 (m), 1413 (m), 1391 (m), 1363 (s), 1332 (m), 1288 (w), 1243 (m), 1168 (m), 1145 (s), 1088 (w), 1046 (m), 967 (w) cm^{-1} — ^1H -NMR (600 MHz, CDCl_3): δ = 1.39–1.42 (m, 24 H, *t*Bu-Me, Me), 1.60–1.68 (m, 6 H, 2- CH_2 , 3- CH_2), 1.94–1.99 (m, 2 H, 2- CH_2 , 3- CH_2), 3.02–3.12 (m, 2 H, 1- CH_2), 3.18 (t, $^3J_{\text{H-H}}$ = 7.26 Hz, 2 H, 1- CH_2), 4.27–4.31 (m, 4 H, CH_2Ph), 4.35 (d, $^2J_{\text{H-H}}$ = 15.72 Hz, 1 H, CH_2Ph), 4.44 (d, $^2J_{\text{H-H}}$ = 15.24 Hz, 1 H, CH_2Ph), 7.12–7.18 (m, 6 H, *o*-Ph-H, *p*-Ph-H), 7.21–7.23 (m, 4 H, *m*-Ph-H), 7.68–7.71 (m, 4 H, 5'-H, 6'-H), 7.78–7.81 (m, 4 H, 4'-H, 7'-H) ppm— ^{13}C -NMR (150 MHz, CDCl_3): δ = 18.90 (Me), 18.94 (Me), 25.37 (CH_2), 25.56 (CH_2), 28.57 (*t*Bu-Me), 30.98 (CH_2), 31.06 (CH_2), 46.10 (1- CH_2), 46.33 (1- CH_2), 47.13 (C-4), 47.32 (C-4), 49.96 (CH_2Ph), 50.65 (CH_2Ph), 79.84 (*t*Bu-C), 79.91 (*t*Bu-C), 123.29 (C-4'), 127.21 (*o*-Ph-CH), 127.28 (*o*-Ph-CH), 127.86 (*p*-Ph-CH), 128.55 (*m*-Ph-CH), 128.60 (*m*-Ph-CH), 131.96 (C-3'a, C-7'a), 132.03 (C-3'a, C-7'a), 134.05 (C-5', C-6'), 134.14 (C-5', C-6'), 138.45 (Ph-C), 138.72 (Ph-C), 168.71 (C-1', C-3') ppm—MS (EI, 70 eV): m/z (%) = 323.2/322.2/321.2 [$\text{M-C}_5\text{H}_9\text{O}_2$] $^+$ (6/22/39), 232.1/231.1 [$\text{M-C}_7\text{H}_7\text{-C}_5\text{H}_9\text{O}_2+\text{H}]^+$ (2/14), 175.0/174.0 [$\text{C}_{10}\text{H}_8\text{NO}_2$] $^+$ (6/28), 121.0/120.0 [$\text{C}_8\text{H}_{10}\text{N}]^+$ (7/74), 107.0/106.0 [$\text{C}_7\text{H}_8\text{N}]^+$ (10/65), 92.0/91.0 [C_7H_7] $^+$ (9/100)—HRMS (ESI) calcd. [$\text{M}+\text{H}]^+$ 323.17540; found 323.17540.

tert-Butyl 4-(1H-Imidazole-1-yl)pentyl(benzyl)carbamate (**29**). NaH (60.7 mg of a 55% oily dispersion, 1.39 mmol) was added to a solution of imidazole (47.3 mg, 0.69 mmol) in DMF (dry, 4 mL) at 0°C under nitrogen atmosphere and the reaction mixture was stirred for 30 min. The bromine compound **5** (312.2 mg, 0.88 mmol) was added at 0°C, and the reaction mixture was allowed to warm up to 25°C and was stirred for further 7 hours. The excess of NaH was carefully hydrolyzed using a small amount of water and the solvent mixture was removed azeotropically with toluene under reduced pressure. Purification with flash column chromatography on silica gel (EtOAc 100%) gave compound **29** (118.9 mg, 50%) as viscous colorless oil. IR (ATR-FTIR): $\tilde{\nu}$ = 2972 (w), 2931 (w), 1682 (s), 1495 (w), 1453 (m), 1413 (m), 1391 (w), 1364 (m), 1278 (w), 1241 (m), 1225 (m), 1163 (s), 1138 (s), 1111 (w), 1076 (w), 1027 (w), 1001 (w), 966 (w), 905 (w), 872 (w), 812 (w), 767 (w), 733 (m), 700 (m), 665 (m), 642 (w), 627 (w) cm^{-1} — ^1H -NMR (600 MHz, CDCl_3 , +3°C): δ = 1.21–1.44 (m, 28 H, Me, *t*Bu-Me, 3- CH_2 , **A**, **B**), 1.61–1.66 (m, 4 H, 2- CH_2 , **A**, **B**), 3.02–3.22 (m, 4 H, 1- CH_2 , **A**, **B**), 4.03–4.09 (m, 1 H, 4-H, **B**), 4.17–4.21 (m, 1 H, 4-H, **A**), 4.30 (s, 2 H, CH_2Ph , **B**), 4.32 (d, $^2J_{\text{H-H}}$ = 15.20 Hz, 1 H, CH_2Ph , **A**), 4.41 (d, $^2J_{\text{H-H}}$ = 15.24 Hz, 1 H, CH_2Ph , **A**),

6.87 (s, 1 H, 2'-H, **B**), 6.91 (s, 1 H, 2'-H, **A**), 7.06–7.09 (m, 2 H, 3'-H, **A**, **B**), 7.13–7.18 (m, 4 H, Ph-H, **A**, **B**), 7.23–7.25 (m, 3 H, Ph-H, **A**, **B**), 7.29 (m, 3 H, Ph-H, **A**, **B**), 7.57 (s, 1 H, 5'-H, **B**), 7.66 (s, 1 H, 5'-H, **A**) ppm— ^{13}C -NMR (150 MHz, CDCl_3 , +3°C): δ = 22.23 (Me, **A**), 22.35 (Me, **B**), 24.39 (C-3, **A**), 24.87 (C-3, **B**), 28.55 (*t*Bu-Me, **A**), 28.62 (*t*Bu-Me, **B**), 34.81 (C-2, **A**), 35.07 (C-2, **B**), 45.45 (C-1, **A**), 45.88 (C-1, **B**), 49.95 (CH_2Ph , **B**), 50.36 (CH_2Ph , **A**), 53.87 (C-4, **A**, **B**), 80.05 (*t*Bu-C, **B**), 80.19 (*t*Bu-C, **A**), 116.58 (C-2', **B**), 116.89 (C-2', **A**), 127.28 (Ph-CH, **A**, **B**), 127.43 (Ph-CH, **A**, **B**), 127.47 (Ph-CH, **A**, **B**), 127.86 (Ph-CH, **A**, **B**), 128.20 (C-3', **A**), 128.70 (Ph-CH, **A**, **B**), 128.92 (C-3', **B**), 135.64 (C-5', **A**), 135.77 (C-5', **B**), 138.30 (Ph-C, **B**), 138.41 (Ph-C, **A**), 155.92 (Boc CO, **A**), 156.11 (Boc CO, **B**) ppm—MS (EI, 70 eV): m/z (%) = 344.3/343.3 [$\text{M}]^{++}$ (11/37), 287.2/286.2 [$\text{M}-\text{C}_4\text{H}_9$] $^+$ (6/5), 271.2/270.2 [$\text{M}-\text{C}_4\text{H}_9\text{O}$] $^+$ (4/19), 243.2/242.2 [$\text{M}-\text{C}_5\text{H}_9\text{O}_2$] $^+$ (3/9), 92.0/91.0 [C_7H_7] $^+$ (9/100)—HRMS (ESI) calcd. [$\text{M}+\text{H}$] $^+$ 344.23325; found 344.23325.

1-Benzyl-2-methylpyrrolidine (17). TFA (985 μL , 1.512 g, and 13.26 mmol) was added to a solution of bromine derivative **5** (94.4 mg, 0.26 mmol) in DCM (5 mL) and the reaction mixture was stirred at 25°C for 1 hour. Dichloromethane was added and the organic layer was washed using aqueous NaOH solution. The organic layer was dried (MgSO_4), filtered, and concentrated. Compound **17** (43.6 mg, 96%) was obtained as beige crystals. Mp 145°C (DCM)—IR (ATR-FTIR): $\tilde{\nu}$ = 2965 (w), 2919 (w), 2846 (w), 2739 (w), 2654 (m), 2592 (m), 2508 (w), 2480 (w), 2360 (s), 2341 (m), 1683 (w), 1496 (w), 1458 (w), 1440 (w), 1416 (w), 1390 (w), 1353 (w), 1330 (w), 1291 (w), 1148 (w), 1072 (m), 1029 (m), 1000 (w) cm^{-1} — ^1H -NMR (600 MHz, CDCl_3): δ = 1.56 (d, $^3J_{\text{H-H}}$ = 6.42 Hz, 6 H, Me), 1.85–1.92 (m, 2 H, 4-H), 2.01–2.08 (m, 2 H, 3-H), 2.14–2.23 (m, 4 H, 3-H, 4-H), 2.84–2.90 (m, 2 H, 5-H), 3.31–3.38 (m, 2 H, 2-H), 3.61–3.66 (m, 2 H, 5-H), 4.11 (d, $^2J_{\text{H-H}}$ = 13.32 Hz, 1 H, CH_2Ph), 4.13 (d, $^2J_{\text{H-H}}$ = 13.32 Hz, 1 H, CH_2Ph), 4.29 (d, $^2J_{\text{H-H}}$ = 13.32 Hz, 1 H, CH_2Ph), 4.32 (d, $^2J_{\text{H-H}}$ = 13.32 Hz, 1 H, CH_2Ph), 7.38–7.42 (m, 6 H, Ph-CH), 7.58–7.60 (m, 4 H, Ph-CH) ppm— ^{13}C -NMR (150 MHz, CDCl_3): δ = 16.07 (Me), 21.09 (C-4), 31.58 (C-3), 52.85 (C-5), 55.89 (CH_2Ph), 63.17 (C-2), 128.83 (Ph-C), 129.51 (Ph-CH), 130.26 (Ph-CH), 131.44 (Ph-CH) ppm—MS (EI, 70 eV): m/z (%) = 176.2/175.2 [$\text{M}]^{++}$ (1/10), 161.1/160.1 [$\text{M}-\text{CH}_3$] $^+$ (12/100), 92.1/91.1 [C_7H_7] $^+$ (6/66)—HRMS (ESI) calcd. [$\text{M}+\text{H}$] $^+$ 176.14338; found 176.14338.

1,1-Dibenzyl-2-methylpyrrolidinium Bromide (18). Cs_2CO_3 (859.6 mg, 2.64 mmol) was added to a solution of (*rac*)-1,4-dibromopentane (500 μL , 843.5 mg, and 3.67 mmol) and dibenzylamine (300 μL , 307.8 mg, and 1.56 mmol) in acetone (10 mL) and the reaction mixture was stirred for 7 hours at 70°C. The mixture was concentrated, the residue was suspended in aqueous NaHCO_3 solution, and the aqueous layer was exhaustively extracted with dichloromethane. The combined organic extracts were dried (MgSO_4), filtered, and concentrated. Purification with flash column chromatography on silica gel (petroleum ether/EtOAc 50:1) gave compound **18** (289.2 mg, 54%) as colorless foam. Mp 198°C (petroleum ether/EtOAc)—IR (ATR-FTIR): $\tilde{\nu}$ = 3726 (w),

3700 (w), 3626 (w), 3595 (w), 3034 (w), 2977 (w), 2921 (w), 2890 (w), 2360 (s), 2341 (s), 1497 (w), 1451 (w), 1406 (w), 1375 (w), 1348 (w), 1311 (w), 1259 (w), 1212 (w), 1186 (w), 1153 (w), 1069 (w), 1036 (w), 1008 (w) cm^{-1} — ^1H -NMR (600 MHz, CDCl_3): δ = 1.83 (d, $^3J_{\text{H-H}}$ = 6.48 Hz, 3 H, Me), 1.94–1.98 (m, 1 H, 4-H), 2.18–2.26 (m, 2 H, 3- CH_2), 2.28–2.31 (m, 1 H, 4-H), 3.03–3.08 (m, 1 H, 5-H), 3.38–3.41 (m, 1 H, 5-H), 3.52–3.59 (m, 1 H, 2-H), 4.22 (d, $^2J_{\text{H-H}}$ = 13.56 Hz, 1 H, CH_2Ph), 4.46 (d, $^2J_{\text{H-H}}$ = 12.84 Hz, 1 H, CH_2Ph), 5.14 (d, $^2J_{\text{H-H}}$ = 12.78 Hz, 1 H, CH_2Ph), 5.68 (d, $^2J_{\text{H-H}}$ = 13.50 Hz, 1 H, CH_2Ph), 7.33–7.37 (m, 4 H, Ph-H), 7.40–7.44 (m, 4 H, Ph-H), 7.82 (d, $^3J_{\text{H-H}}$ = 6.36 Hz, 2 H, *p*-Ph-H) ppm— ^{13}C -NMR (150 MHz, CDCl_3): δ = 14.36 (Me), 19.12 (C-4), 28.41 (C-3), 54.91 (C-5), 57.52 (CH_2Ph), 60.22 (CH_2Ph), 67.35 (C-2), 127.09 (Ph-C), 127.75 (Ph-C), 129.50 (Ph-CH), 129.52 (Ph-CH), 130.74 (Ph-CH), 130.76 (Ph-CH), 133.41 (Ph-CH), 133.82 (Ph-CH) ppm—MS (EI, 70 eV): m/z (%) = 175.1 [$\text{M}-\text{C}_7\text{H}_7$] $^{++}$ (5), 161.1/160.1 [$\text{M}-\text{C}_8\text{H}_{10}$] $^+$ (5/43), 92.1/91.1 [C_7H_7] $^+$ (6/100)—HRMS (ESI) calcd. [$\text{M}]^+$ 266.19033; found 266.19018.

tert-Butyl Benzyl(4-bromobutyl)carbamate (19). NaH (3.048 g of a 55% oily dispersion, 69.8 mmol) was added to a solution of Boc protected benzylamine (4.789 g, 21.6 mmol) in DMF (dry, 50 mL) at 0°C under nitrogen atmosphere and the reaction mixture was stirred for 30 min at 0°C. 1,4-Dibromobutane (8.3 mL, 15.006 g, and 69.5 mmol) was added at 0°C and the mixture was stirred for further 3 hours. The excess of NaH was carefully hydrolysed with water and the mixture was exhaustively extracted with dichloromethane. The combined organic extracts were dried (MgSO_4) and filtered and the solvent mixture was removed azeotropically with toluene under reduced pressure. Purification with flash column chromatography on silica gel (petroleum ether/EtOAc 10:1) gave product **19** (2.019 g, 27%) and the elimination product **21** (501.4 mg, 9%) both as colorless oils. Compound **7**: IR (ATR-FTIR): $\tilde{\nu}$ = 2971 (w), 2931 (w), 1687 (s), 1454 (m), 1413 (m), 1363 (m), 1299 (w), 1241 (m), 1151 (s), 1108 (w), 1074 (w), 1029 (w) cm^{-1} — ^1H -NMR (600 MHz, CDCl_3 , +2°C): δ = 1.41 (s, 9 H, *t*Bu-Me), 1.48 (s, 9 H, *t*Bu-Me), 1.56–1.66 (m, 4 H, 2- CH_2), 1.75–1.82 (m, 4 H, 3- CH_2), 3.12 (t, $^3J_{\text{H-H}}$ = 7.08 Hz, 2 H, 1- CH_2), 3.22 (t, $^3J_{\text{H-H}}$ = 7.20 Hz, 2 H, 1- CH_2), 3.34–3.39 (m, 4 H, 4- CH_2), 4.38 (s, 2 H, CH_2Ph), 4.43 (s, 2 H, CH_2Ph), 7.18–7.25 (m, 6 H, *o*-Ph-H, *p*-Ph-H), 7.29–7.32 (m, 4 H, *m*-Ph-H) ppm— ^{13}C -NMR (150 MHz, CDCl_3 , +2°C): δ = 26.54 (C-2), 26.77 (C-2), 28.56 (*t*Bu-Me), 28.63 (*t*Bu-Me), 30.05 (C-3), 33.67 (C-4), 33.92 (C-4), 45.41 (C-1), 45.50 (C-1), 49.74 (CH_2Ph), 50.39 (CH_2Ph), 80.03 (*t*Bu-C), 80.05 (*t*Bu-C), 127.29 (Ph-CH), 127.35 (Ph-CH), 127.41 (Ph-CH), 127.85 (Ph-CH), 128.68 (*m*-Ph-CH), 128.71 (*m*-Ph-CH), 138.34 (Ph-C), 138.57 (Ph-C), 155.84 (Boc CO), 156.19 (Boc CO) ppm—MS (EI, 70 eV): m/z (%) = 287.1/286.1/285.1 [$\text{M}-\text{C}_4\text{H}_8$] $^{++}$ (30/8/29), 91.1 [C_7H_7] $^+$ (100)—HRMS (ESI) calcd. [$\text{M}+\text{H}$] $^+$ 342.10632; found 342.10631.

tert-Butyl Benzyl(but-3-enyl)carbamate (21). IR (ATR-FTIR): $\tilde{\nu}$ = 3068 (w), 2975 (w), 2927 (w), 1689 (s), 1643 (w), 1455 (m), 1411 (m), 1365 (m), 1294 (w), 1241 (m), 1166 (s), 1141 (s), 1027 (w), 997 (w) cm^{-1} — ^1H -NMR (600 MHz, CDCl_3 , +2°C): δ = 1.41 (s, 9 H, *t*Bu-Me), 1.48 (s, 9 H, *t*Bu-Me), 2.18–2.21

(m, 2 H, 2-CH₂), 2.23–2.27 (m, 2 H, 2-CH₂), 3.13–3.16 (m, 2 H, 1-CH₂), 3.24–3.27 (m, 2 H, 1-CH₂), 4.39 (s, 2 H, CH₂Ph), 4.43 (s, 2 H, CH₂Ph), 4.97 (d, ³J_{H-H} = 9.78 Hz, 2 H, 4-H), 5.02 (d, ³J_{H-H} = 17.70 Hz, 2 H, 4-H), 5.66–5.77 (m, 2 H, 3-H), 7.18–7.24 (m, 6 H, *o*-Ph-H, *p*-Ph-H), 7.29–7.31 (*m*-Ph-H) ppm—¹³C-NMR (150 MHz, CDCl₃, +2°C): δ = 28.56 (*t*Bu-Me), 28.62 (*t*Bu-Me), 32.59 (C-2), 33.02 (C-2), 46.13 (C-1), 46.24 (C-1), 50.04 (CH₂Ph), 50.74 (CH₂Ph), 79.85 (*t*Bu-C), 79.94 (*t*Bu-C), 116.74 (C-4), 116.82 (C-4), 127.26 (Ph-CH), 127.34 (Ph-CH), 127.84 (Ph-CH), 128.63 (*m*-Ph-CH), 128.68 (*m*-Ph-CH), 135.65 (C-3), 138.47 (Ph-C), 138.74 (Ph-C), 155.76 (Boc CO), 156.21 (Boc CO) ppm—MS (EI, 70 eV): *m/z* (%) = 207.2/206.2 [M-C₄H₇]⁺ (3/25), 91.1 [C₇H₇]⁺ (100)—HRMS (ESI) calcd. [M+Na]⁺ 284.16210; found 284.16208.

tert-Butyl 4-Azidobutyl(benzyl)carbamate (**23**). A reaction mixture consisting of bromine **19** (214.3 mg, 0.63 mmol) and NaN₃ (122.6 mg, 1.89 mmol) in DMF (dry, 2 mL) was stirred for 24 hours at 25°C. The complete conversion was determined by ¹H-NMR spectroscopy. DMF was removed azeotropically with toluene under reduced pressure, and the residue was suspended in dichloromethane, filtered (Celite), and concentrated. Purification with flash column chromatography on silica gel (petroleum ether/EtOAc 20:1) gave azide **23** (165.0 mg, 86%) as colorless oil. IR (ATR-FTIR): $\tilde{\nu}$ = 2973 (w), 2931 (w), 2869 (w), 2092 (s), 1689 (s), 1454 (m), 1413 (s), 1363 (m), 1243 (s), 1160 (s), 1126 (s), 1074 (w), 1027 (w), 1000 (w) cm⁻¹—¹H-NMR (600 MHz, CDCl₃, +2°C): δ = 1.41 (s, 9 H, *t*Bu-Me), 1.48 (s, 9 H, *t*Bu-Me), 1.51–1.54 (m, 8 H, 2-CH₂, 3-CH₂), 3.10–3.14 (m, 2 H, 1-CH₂), 3.20–3.25 (m, 6 H, 1-CH₂, 4-CH₂), 4.38 (s, 2 H, CH₂Ph), 4.43 (s, 2 H, CH₂Ph), 7.18–7.26 (m, 6 H, *o*-Ph-CH, *p*-Ph-CH), 7.29–7.32 (m, 4 H, *m*-Ph-CH) ppm—¹³C-NMR (150 MHz, CDCl₃, +2°C): δ = 25.16 (CH₂), 25.44 (CH₂), 26.26 (CH₂), 26.32 (CH₂), 28.56 (*t*Bu-Me), 28.62 (*t*Bu-Me), 45.84 (1-CH₂), 45.94 (1-CH₂), 49.81 (CH₂Ph), 50.47 (CH₂Ph), 51.17 (C-4), 51.29 (C-4), 80.00 (*t*Bu-C), 80.06 (*t*Bu-C), 127.26 (Ph-CH), 127.35 (Ph-CH), 127.41 (Ph-CH), 127.83 (Ph-CH), 128.68 (Ph-CH), 128.71 (Ph-CH), 138.36 (Ph-C), 138.59 (Ph-C), 155.85 (Boc CO), 156.19 (Boc CO) ppm—MS (EI, 70 eV): *m/z* (%) = 203.1 [M-C₅H₉O₂]⁺ (7), 91.0 [C₇H₇]⁺ (100)—HRMS (ESI) calcd. [M+Na]⁺ 327.17915; found 327.17915.

tert-Butyl 4-Aminobutyl(benzyl)carbamate (**25**). NaN₃ (177.7 mg, 2.73 mmol) and PPh₃ (482.4 mg, 1.84 mmol) were added to a solution of bromine derivative **19** (311.9 mg, 0.91 mmol) in DMF (dry, 5 mL) and the reaction mixture was stirred for 24 hours at 25°C. Pulverised KOH (165.4 mg, 2.95 mmol) was added and stirred for further 24 hours at 25°C. DMF was removed using high vacuum, the residue was suspended in water, and the mixture was exhaustively extracted with dichloromethane. The combined organic extracts were dried (MgSO₄), filtered, and concentrated. Purification with flash column chromatography on deactivated silica gel (DCM/MeOH 20:1) gave amine **25** (119.9 mg, 47%) as colorless oil. IR (ATR-FTIR): $\tilde{\nu}$ = 2972 (w), 2925 (w), 2855 (w), 1685 (s), 1574 (w), 1494 (w), 1465 (m), 1454 (m), 1414 (s), 1390 (w), 1364 (m), 1305 (w), 1242 (m), 1163 (s), 1073 (w), 1028 (w) cm⁻¹—¹H-NMR (600 MHz, CDCl₃,

+2°C): δ = 1.33–1.54 (m, 26 H, 2-CH₂, 3-CH₂, *t*Bu-Me), 2.62–2.65 (m, 4 H, 4-CH₂), 3.08–3.10 (m, 2 H, 1-CH₂), 3.17–3.20 (m, 2 H, 1-CH₂), 4.38 (s, 2 H, CH₂Ph), 4.42 (s, 2 H, CH₂Ph), 7.17–7.22 (m, 6 H, *o*-Ph-H, *p*-Ph-H), 7.28–7.31 (m, 4 H, *m*-Ph-H) ppm—¹³C-NMR (150 MHz, CDCl₃, +2°C): δ = 25.31 (CH₂), 25.60 (CH₂), 28.57 (*t*Bu-Me), 28.64 (*t*Bu-Me), 30.95 (CH₂), 31.01 (CH₂), 42.00 (C-4), 42.30 (C-4), 46.31 (C-1), 46.55 (C-1), 49.82 (CH₂Ph), 50.54 (CH₂Ph), 79.76 (*t*Bu-C), 79.90 (*t*Bu-C), 127.23 (Ph-CH), 127.26 (Ph-CH), 127.32 (Ph-CH), 127.81 (Ph-CH), 128.62 (*m*-Ph-CH), 128.66 (*m*-Ph-CH), 138.54 (Ph-C), 138.78 (Ph-C), 155.82 (Boc CO), 156.26 (Boc CO) ppm—MS (EI, 70 eV): *m/z* (%) = 279.2/278.2 [M]⁺⁺ (1/3), 223.1/222.1 [M-C₄H₈]⁺⁺ (3/16), 178.1/177.1 [M-C₅H₉O₂]⁺ (2/13), 91.1 [C₇H₇]⁺ (100)—HRMS (ESI) calcd. [M+H]⁺ 279.20670; found 279.20671.

tert-Butyl Benzyl(10-bromodecyl)carbamate (**20**). NaH (2.498 g of a 55% oily dispersion, 57.2 mmol) was added to a solution of Boc protected benzylamine (4.011 g, 19.4 mmol) in DMF (dry, 50 mL) at 0°C under nitrogen atmosphere and the reaction mixture was stirred for 30 min at 0°C. 1,10-Dibromodecane (13.0 mL, 17.355 g, and 57.8 mmol) was added at 0°C and the mixture was stirred for further 3.5 hours. The excess of NaH was hydrolysed carefully using water and the mixture was exhaustively extracted with dichloromethane. The combined organic extracts were dried (MgSO₄) and the solvent mixture was removed azeotropically with toluene under reduced pressure. Purification with flash column chromatography on silica gel (petroleum ether/EtOAc 40:1) gave product **20** (3.604 g, 44%) and the elimination product **22** (304.6 mg, 5%) both as colorless oils. Compound **20**: IR (ATR-FTIR): $\tilde{\nu}$ = 2971 (w), 2925 (m), 2854 (w), 1689 (s), 1455 (m), 1413 (m), 1363 (m), 1303 (w), 1240 (m), 1164 (s), 1027 (w) cm⁻¹—¹H-NMR (600 MHz, CDCl₃, +2°C): δ = 1.16–1.28 (m, 20 H, 3-CH₂, 4-CH₂, 5-CH₂, 6-CH₂, 7-CH₂), 1.37–1.47 (m, 26 H, *t*Bu-Me, 2-CH₂, 8-CH₂), 1.79–1.83 (m, 4 H, 9-CH₂), 3.06 (t, ³J_{H-H} = 7.26 Hz, 1-CH₂), 3.16 (t, ³J_{H-H} = 7.56 Hz, 1-CH₂), 3.39 (t, ³J_{H-H} = 6.84 Hz, 4 H, 10-CH₂), 4.37 (s, 2 H, CH₂Ph), 4.42 (s, 2 H, CH₂Ph), 7.18–7.24 (m, 6 H, *o*-Ph-H, *p*-Ph-H), 7.29–7.31 (m, 4 H, *m*-Ph-H) ppm—¹³C-NMR (150 MHz, CDCl₃, +2°C): δ = 26.94 (C-3), 27.02 (C-3), 28.00 (C-2), 28.15 (C-2), 28.32 (C-8), 28.58 (*t*Bu-Me), 28.65 (*t*Bu-Me), 28.92 (CH₂), 29.44 (CH₂), 29.53 (CH₂), 29.55 (CH₂), 29.65 (CH₂), 32.95 (C-9), 32.96 (C-9), 34.49 (C-10), 34.52 (C-10), 46.42 (C-1), 46.75 (C-1), 49.73 (CH₂Ph), 50.43 (CH₂Ph), 79.63 (*t*Bu-C), 79.77 (*t*Bu-C), 127.19 (Ph-CH), 127.21 (Ph-CH), 127.25 (Ph-CH), 127.79 (Ph-CH), 128.59 (*m*-Ph-CH), 128.63 (*m*-Ph-CH), 138.63 (Ph-C), 138.92 (Ph-C), 155.81 (Boc CO), 156.35 (Boc CO) ppm—MS (EI, 70 eV): *m/z* (%) = 371.2/370.2/369.2 [M-C₄H₈]⁺⁺ (21/8/20), 91.1 [C₇H₇]⁺ (100)—HRMS (ESI) calcd. [M+Na]⁺ 448.18216; found 448.18218.

tert-Butyl Benzyl(dec-9-enyl)carbamate (**22**). IR (ATR-FTIR): $\tilde{\nu}$ = 2973 (w), 2925 (m), 2854 (w), 1691 (s), 1641 (w), 1455 (m), 1413 (m), 1363 (m), 1303 (w), 1241 (m), 1164 (s), 1029 (w), 993 (w) cm⁻¹—¹H-NMR (600 MHz, CDCl₃, +2°C): δ = 1.16–1.25 (m, 16 H, 3-CH₂, 4-CH₂, 5-CH₂, 6-CH₂), 1.30–1.35 (m, 4 H, 7-CH₂), 1.40–1.47 (m, 22 H, *t*Bu-Me, 2-CH₂,

1.97–2.03 (m, 4 H, 8-CH₂), 3.06 (t, $^3J_{\text{H-H}} = 7.26$ Hz, 1-CH₂), 3.16 (t, $^3J_{\text{H-H}} = 7.56$ Hz, 1-CH₂), 4.37 (s, 2 H, CH₂Ph), 4.42 (s, 2 H, CH₂Ph), 4.90 (d, $^3J_{\text{H-H}} = 9.96$ Hz, 2 H, 10-H), 4.97 (d, $^3J_{\text{H-H}} = 17.16$ Hz, 2 H, 10-H), 5.75–5.82 (m, 2 H, 9-H), 7.18–7.24 (m, 6 H, *o*-Ph-H, *p*-Ph-H), 7.28–7.31 (m, 4 H, *m*-Ph-H) ppm—¹³C-NMR (150 MHz, CDCl₃, +2°C): δ = 26.93 (CH₂), 27.03 (CH₂), 28.00 (C-2), 28.14 (C-2), 28.58 (*t*Bu-Me), 28.64 (*t*Bu-Me), 29.04 (C-7), 29.23 (CH₂), 29.43 (CH₂), 29.53 (CH₂), 29.61 (CH₂), 34.01 (C-8), 46.42 (C-1), 46.76 (C-1), 49.72 (CH₂Ph), 50.43 (CH₂Ph), 79.62 (*t*Bu-C), 79.76 (*t*Bu-C), 114.32 (C-10), 114.37 (C-10), 127.18 (Ph-CH), 127.22 (Ph-CH), 127.25 (Ph-CH), 127.79 (Ph-CH), 128.58 (*m*-Ph-CH), 128.63 (*m*-Ph-CH), 138.63 (Ph-C), 138.92 (Ph-C), 139.41 (C-9), 139.47 (C-9), 155.80 (Boc CO), 156.36 (Boc CO) ppm—MS (EI, 70 eV): m/z (%) = 292.4/291.4/290.4 [M-C₄H₈+H]⁺ (1/8/40), 247.3/246.3/245.3 [M-Boc]⁺⁺ (4/21/1), 91.1 [Bn]⁺ (100)—HRMS (ESI) calcd. [M+Na]⁺ 368.25600; found 368.25601 [M+Na]⁺.

tert-Butyl 5-Azidopentyl(benzyl)carbamate (24). A suspension consisting of bromine derivative **20** (249.0 mg, 0.58 mmol) and NaN₃ (115.2 mg, 1.77 mmol) in DMF (dry, 2 mL) was stirred for 24 hours at 25°C. The complete conversion was determined by ¹H-NMR spectroscopy. DMF was removed azeotropically with toluene under reduced pressure, and the residue was suspended in dichloromethane, filtered (Celite), and concentrated. Purification with flash column chromatography on silica gel (petroleum ether/EtOAc 20:1) gave azide **24** (214.9 mg, 95%) as colorless oil. IR (ATR-FTIR): $\tilde{\nu}$ = 2973 (w), 2925 (w), 2854 (w), 2092 (m), 1691 (s), 1455 (m), 1413 (m), 1363 (m), 1241 (m), 1164 (s), 1093 (w), 1029 (w) cm⁻¹—¹H-NMR (600 MHz, CDCl₃, +2°C): δ = 1.16–1.26 (m, 24 H, 2-CH₂, 3-CH₂, 4-CH₂, 5-CH₂, 6-CH₂, 7-CH₂), 1.29–1.35 (m, 4 H, 8-CH₂), 1.40 (s, 9 H, *t*Bu-Me), 1.47 (s, 9 H, *t*Bu-Me), 1.55–1.57 (m, 4 H, 9-CH₂), 3.06 (t, $^3J_{\text{H-H}} = 7.20$ Hz, 2 H, 1-CH₂), 3.16 (t, $^3J_{\text{H-H}} = 7.56$ Hz, 2 H, 1-CH₂), 3.23 (t, $^3J_{\text{H-H}} = 6.84$ Hz, 4 H, 10-CH₂), 4.37 (s, 2 H, CH₂Ph), 4.42 (s, 2 H, CH₂Ph), 7.18–7.24 (m, 6 H, *o*-Ph-H, *p*-Ph-H), 7.29–7.31 (m, 4 H, *m*-Ph-H) ppm—¹³C-NMR (150 MHz, CDCl₃, +2°C): δ = 26.87 (C-8), 26.95 (CH₂), 27.03 (CH₂), 28.00 (C-2), 28.15 (C-2), 28.59 (*t*Bu-Me), 28.65 (*t*Bu-Me), 28.99 (C-9), 29.31 (CH₂), 29.33 (CH₂), 29.46 (CH₂), 29.53 (CH₂), 29.58 (CH₂), 29.61 (CH₂), 29.67 (CH₂), 46.41 (C-1), 46.75 (C-1), 49.72 (CH₂Ph), 50.43 (CH₂Ph), 51.61 (C-10), 79.62 (*t*Bu-C), 79.77 (*t*Bu-C), 127.19 (Ph-CH), 127.22 (Ph-CH), 127.26 (Ph-CH), 127.79 (Ph-CH), 128.59 (*m*-Ph-CH), 128.63 (*m*-Ph-CH), 138.64 (Ph-C), 138.93 (Ph-C), 155.81 (Boc CO), 156.35 (Boc CO) ppm—MS (EI, 70 eV): m/z (%) = 288.2/287.1 [M-C₅H₉O₂]⁺ (2/11), 91.0 [C₇H₇]⁺ (100)—HRMS (ESI) calcd. [M+H]⁺ 389.29110; found 389.29110.

tert-Butyl 10-Aminodecyl(benzyl)carbamate (26). NaN₃ (149.2 mg, 2.30 mmol) and PPh₃ (402.6 mg, 1.53 mmol) were added to a solution of bromine derivative **20** (321.5 mg, 0.75 mmol) in DMF (dry, 5 mL) and the reaction mixture was stirred for 24 hours at 25°C. Pulverized KOH (127.1 mg, 2.27 mmol) was added and the mixture was stirred for further 24 hours at 25°C. DMF was removed using high

vacuum, the residue was suspended in water, and the mixture was exhaustively extracted with dichloromethane. The combined organic extracts were dried (MgSO₄), filtered, and concentrated. Purification on deactivated silica gel (DCM/MeOH 20:1) gave compound **26** (105.9 mg, 39%) as colorless oil. IR (ATR-FTIR): $\tilde{\nu}$ = 2970 (w), 2923 (m), 2852 (m), 1690 (s), 1570 (w), 1494 (w), 1454 (m), 1414 (m), 1390 (w), 1364 (m), 1305 (w), 1240 (m), 1164 (s), 1028 (w) cm⁻¹—¹H-NMR (600 MHz, CDCl₃, +2°C): δ = 1.16–1.27 (m, 24 H, 2-CH₂, 3-CH₂, 4-CH₂, 5-CH₂, 6-CH₂, 7-CH₂), 1.39–1.46 (m, 26 H, *t*Bu-Me, 8-CH₂, 9-CH₂), 1.72 (s, br, 4 H, NH₂), 2.63–2.65 (m, 4 H, 10-CH₂), 3.05–3.07 (m, 2 H, 1-CH₂), 3.14–3.17 (m, 2 H, 1-CH₂), 4.37 (s, 2 H, CH₂Ph), 4.42 (s, 2 H, CH₂Ph), 7.17–7.23 (m, 6 H, *o*-Ph-H, *p*-Ph-H), 7.28–7.30 (m, 4 H, *m*-Ph-H) ppm—¹³C-NMR (150 MHz, CDCl₃, +2°C): δ = 26.95 (CH₂), 27.04 (CH₂), 28.00 (CH₂), 28.14 (CH₂), 28.57 (*t*Bu-Me), 28.64 (*t*Bu-Me), 29.48 (CH₂), 29.56 (CH₂), 29.64 (CH₂), 29.66 (CH₂), 29.73 (CH₂), 33.84 (9-CH₂), 42.32 (10-CH₂), 46.41 (1-CH₂), 46.76 (1-CH₂), 49.71 (CH₂Ph), 50.42 (CH₂Ph), 79.60 (*t*Bu-C), 79.75 (*t*Bu-C), 127.17 (Ph-CH), 127.21 (Ph-CH), 127.24 (Ph-CH), 127.78 (Ph-CH), 128.58 (*m*-Ph-CH), 128.62 (*m*-Ph-CH), 138.63 (Ph-C), 138.92 (Ph-C), 155.79 (Boc CO), 156.35 (Boc CO) ppm—MS (EI, 70 eV): m/z (%) = 363.3/362.3 [M]⁺⁺ (2/5), 306.2 [M-C₄H₈]⁺⁺ (2), 263.2/262.2/261.2 [M-C₅H₉O₂]⁺ (2/13/46), 91.1 [C₇H₇]⁺ (100)—HRMS (ESI) calcd. [M+H]⁺ 363.30060; found 363.30060.

N-Benzyl-3,3-dimethylbutanamide (31). 3,3-Dimethylbutanoyl chloride (7.9 mL, 7.655 g, and 56.9 mmol) was added to a solution of benzylamine (5.073 g, 47.3 mmol) and triethylamine (9.9 mL, 7.187 g, and 71.0 mmol) in DCM (dry, 60 mL) at 0°C. The reaction mixture was stirred for 15 min at 0°C, aqueous NaOH solution was added, and the mixture was exhaustively extracted with dichloromethane. The combined organic extracts were dried (MgSO₄), filtered, and concentrated. The residue was purified using flash column chromatography on silica gel (petroleum ether/EtOAc 5:1) to give product **31** (9.162 g, 94%) as colorless solid. Mp 72°C (petroleum ether/EtOAc)—IR (ATR-FTIR): $\tilde{\nu}$ = 3278 (w, br), 3060 (w), 3028 (w), 2954 (w), 2865 (w), 2357 (w), 2335 (w), 1633 (s), 1542 (s), 1497 (m), 1461 (m), 1391 (w), 1364 (m), 1338 (m), 1266 (m), 1234 (m), 1202 (w), 1148 (w), 1072 (w), 1030 (w), 1009 (w) cm⁻¹—¹H-NMR (600 MHz, CDCl₃): δ = 1.03 (s, 9 H, *t*Bu-Me), 2.07 (s, 2 H, 2-CH₂), 4.41 (d, $^3J_{\text{H-H}} = 5.64$ Hz, 2 H, CH₂Ph), 5.68 (s, br, 1 H, NH), 7.25–7.27 (m, 3 H, *o*-Ph-H, *p*-Ph-H), 7.30–7.32 (m, 2 H, *m*-Ph-H) ppm—¹³C-NMR (150 MHz, CDCl₃): δ = 30.07 (*t*Bu-Me), 31.17 (*t*Bu-C), 43.82 (CH₂Ph), 50.82 (C-2), 127.69 (*p*-Ph-C), 128.12 (*o*-Ph-C), 128.90 (*m*-Ph-C), 138.66 (Ph-C), 171.74 (amide CO) ppm—MS (EI, 70 eV): m/z (%) = 206.4/205.4 [M]⁺⁺ (8/48), 149.2/148.2 [M-C₄H₉]⁺ (80/48), 92.1/91.1 [C₇H₇]⁺ (14/100)—HRMS (ESI) calc. [M+H]⁺ 206.15394; found 206.15394.

N-Benzyl-N-(4'-bromopentyl)-3,3-dimethylbutanamide (32). NaH (943.2 mg of a 55% oily dispersion, 21.6 mmol) was added to a solution of **31** (1.486 g, 7.24 mmol) in DMF (dry, 20 mL) at 0°C under nitrogen atmosphere and the reaction mixture was stirred for 30 min at 0°C. 1,4-Dibromopentane

(2.2 mL, 3.711 g, and 16.1 mmol) was added at 0°C, and the reaction mixture was allowed to warm up to 25°C and was stirred for further 6 hours. After addition of aqueous NaCl solution the mixture was exhaustively extracted with dichloromethane, the combined organic extracts were dried (MgSO₄) and filtered, and the solvent mixture was removed azeotropically with toluene under reduced pressure. Purification with flash column chromatography on silica gel (petroleum ether/EtOAc 10 : 1) gave compound **32** (564.4 mg, 22%) and compound **33** (93.8 mg, 5%) both as colorless oil. Compound **32**: IR (ATR-FTIR): $\tilde{\nu}$ = 2951 (m), 2865 (w), 1635 (s), 1495 (w), 1451 (m), 1416 (m), 1361 (m), 1324 (w), 1229 (m), 1186 (m), 1152 (m), 1121 (m), 1078 (w), 1028 (m), 957 (m) cm⁻¹—¹H-NMR (600 MHz, CDCl₃): δ = 1.04 (s, 9 H, *t*Bu-Me, **A**), 1.07 (s, 9 H, *t*Bu-Me, **B**), 1.66 (d, ³*J*_{H-H} = 6.66 Hz, 6 H, Me, **A**, **B**), 1.69–1.77 (m, 8 H, 2'-CH₂, 3'-CH₂, **A**, **B**), 2.24 (dd, ²*J*_{H-H} = 14.40 Hz, 2 H, 2-CH₂, **A**), 2.29 (dd, ²*J*_{H-H} = 14.22 Hz, 2 H, 2-CH₂, **B**), 3.16–3.27 (m, 2 H, 1'-CH₂, **B**), 3.28–3.33 (m, 1 H, 1'-CH₂, **A**), 3.37–3.41 (m, 1 H, 1'-CH₂, **A**), 4.02–4.05 (m, 1 H, 4'-H, **B**), 4.10–4.13 (m, 1 H, 4'-H, **A**), 4.55 (dd, ²*J*_{H-H} = 17.04 Hz, 2 H, CH₂Ph, **A**), 4.60 (s, 2 H, CH₂Ph, **B**), 7.14 (d, ³*J*_{H-H} = 7.50 Hz, 2 H, *o*-Ph-H, **A**), 7.23–7.25 (m, 3 H, *o*-Ph-H, *p*-Ph-H, **B**), 7.26–7.30 (m, 3 H, *m*-Ph-H, *p*-Ph-H, **A**), 7.33–7.35 (m, 2 H, *m*-Ph-H) ppm—¹³C-NMR (150 MHz, CDCl₃): δ = 26.09 (CH₂, **A**), 26.73 (Me, **A**, **B**), 26.94 (CH₂, **B**), 30.26 (*t*Bu-Me, **A**), 30.35 (*t*Bu-Me, **B**), 31.73 (*t*Bu-C, **A**), 31.84 (*t*Bu-C, **B**), 38.15 (CH₂, **B**), 38.54 (CH₂, **A**), 44.82 (C-2, **B**), 45.06 (C-2, **A**), 47.00 (C-1', **B**), 48.20 (CH₂Ph, **B**), 50.74 (C-4', **B**), 51.57 (C-4', **A**), 51.84 (CH₂Ph, **A**), 126.54 (*o*-Ph-CH, **A**), 127.46 (*p*-Ph-CH, **B**), 127.80 (*p*-Ph-CH, **A**), 128.32 (*o*-Ph-CH, **B**), 128.75 (*m*-Ph-CH), 129.10 (*m*-Ph-CH), 137.24 (Ph-C, **A**), 138.31 (Ph-C, **B**), 172.13 (C-1, **B**), 172.58 (C-1, **A**) ppm—MS (EI, 70 eV): *m/z* (%) = 355.1/354.1/353.1 [M]⁺ (10/2/10), 275.2/274.2 [M-Br]⁺ (12/55), 219.2/218.2 [M-C₄H₈Br]⁺ (8/50), 121.1/120.1 [C₈H₁₀N]⁺ (6/61), 92.0/91.0 [C₇H₇]⁺ (9/100)—HRMS (ESI) calcd. [M+H]⁺ 354.14270; found 354.14272.

(*E*)-*N*-Benzyl-3,3-dimethyl-*N*-(pent-3'-enyl)butanamide (**33**). IR (ATR-FTIR): $\tilde{\nu}$ = 2954 (m), 2868 (w), 1735 (w), 1642 (s), 1495 (w), 1452 (m), 1414 (m), 1388 (w), 1360 (m), 1226 (m), 1183 (m), 1129 (w), 1078 (w), 1027 (w), 969 (m) cm⁻¹—¹H-NMR (600 MHz, CDCl₃): δ = 0.93–0.98 (m, 6 H, Me, **A**, **B**), 1.04 (s, 9 H, *t*Bu-Me, **B**), 1.07 (s, 9 H, *t*Bu-Me, **A**), 1.99–2.05 (m, 4 H, 2'-CH₂, **A**, **B**), 2.26 (s, 2 H, 2-CH₂, **B**), 2.29 (s, 2 H, 2-CH₂, **A**), 3.77 (d, ³*J*_{H-H} = 4.44 Hz, 2 H, 1'-CH₂, **A**), 3.92 (d, ³*J*_{H-H} = 5.58 Hz, 1'-CH₂, **B**), 4.50 (s, 2 H, CH₂Ph, **B**), 4.56 (s, 2 H, CH₂Ph, **A**), 5.28–5.30 (m, 1 H, 3'-H, **A**), 5.36–5.38 (m, 1 H, 3'-H, **B**), 5.52–5.58 (m, 2 H, 4'-H, **A**, **B**), 7.13–7.14 (m, 2 H, Ph-H), 7.22–7.33 (m, 8 H, Ph-H) ppm—¹³C-NMR (150 MHz, CDCl₃): δ = 13.68 (Me, **A**, **B**), 25.45 (C-2', **A**), 30.25 (*t*Bu-Me, **B**), 30.33 (*t*Bu-Me, **A**), 31.71 (*t*Bu-C, **A**, **B**), 44.81 (C-2, **A**), 45.00 (C-2, **B**), 47.23 (C-1', **B**), 47.85 (CH₂Ph, **A**), 49.38 (C-1', **A**), 50.63 (CH₂Ph, **B**), 123.49 (C-3', **A**), 124.04 (C-3', **B**), 126.62 (Ph-CH), 127.41 (Ph-CH), 127.64 (Ph-CH), 128.46 (Ph-CH), 128.67 (Ph-CH), 129.00 (Ph-CH), 135.63 (C-4', **A**), 136.21 (C-4', **B**), 137.38 (Ph-C, **B**), 138.36 (Ph-C, **A**), 172.32 (amide CO, **B**), 172.38 (amide CO, **A**) ppm—MS (EI, 70 eV): *m/z* (%) = 274.2/273.2 [M]⁺ (7/24), 259.2/258.2 [C₁₇H₂₄NO]⁺

(3/16), 205.1/204.1 [C₁₃H₁₈NO]⁺ (8/56), 183.1/182.1 [M-C₇H₇]⁺ (5/43), 107.0/106.0 [C₇H₈N]⁺ (17/97), 92.0/91.0 [C₇H₇]⁺ (10/100), 85.0/84.0 [C₅H₁₀N]⁺ (6/85). HRMS (ESI) calcd. [M+H]⁺ 274.21654; found 274.21655.

N-(4'-Azidopentyl)-*N*-benzyl-3,3-dimethylbutanamide (**34**). A suspension of the bromine compound **32** (199.2 mg, 0.56 mmol) and NaN₃ (108.4 mg, 1.67 mmol) in DMF (dry, 5 mL) was stirred at 25°C for 24 hours. DMF was removed azeotropically with toluene under reduced pressure, and the residue was suspended in dichloromethane, filtered (Celite), and concentrated. Purification with flash column chromatography on silica gel (petroleum ether/EtOAc 10 : 1) gave compound **34** (169.1 mg, 95%) as colorless oil. IR (ATR-FTIR): $\tilde{\nu}$ = 2950 (m), 2866 (w), 2097 (s), 1636 (s), 1495 (w), 1452 (m), 1416 (m), 1378 (m), 1361 (m), 1327 (m), 1233 (m), 1186 (m), 1120 (m), 1078 (w), 1028 (w), 954 (w) cm⁻¹—¹H-NMR (600 MHz, CDCl₃): δ = 1.04 (s, 9 H, *t*Bu, **A**), 1.07 (s, 9 H, *t*Bu, **B**), 1.22 (t, ³*J*_{H-H} = 6.68 Hz, 6 H, Me), 1.36–1.39 (m, 2 H, 3'-CH₂, **B**), 1.41–1.44 (m, 2 H, 3'-CH₂, **A**), 1.52–1.67 (m, 4 H, 2'-CH₂), 2.24 (s, 2 H, 2-CH₂, **A**), 2.28 (s, 2 H, 2-CH₂, **B**), 3.21 (t, ³*J*_{H-H} = 7.68 Hz, 2 H, 1-CH₂, **B**), 3.29–3.44 (m, 4 H, 1-CH₂, **A**; 4'-H, **A**, **B**), 4.54 (s, 2 H, CH₂Ph, **A**), 4.59 (s, 2 H, CH₂Ph, **B**), 7.13–7.14 (m, 2 H, Ph-H), 7.22–7.24 (m, 3 H, Ph-H), 7.26–7.30 (m, 3 H, Ph-H), 7.33–7.35 (m, 2 H, Ph-H) ppm—¹³C-NMR (150 MHz, CDCl₃): δ = 19.68 (Me), 24.43 (C-2', **A**), 25.32 (C-2', **B**), 30.24 (*t*Bu-Me, **A**), 30.35 (*t*Bu-Me, **B**), 31.73 (*t*Bu-C, **A**), 31.83 (*t*Bu-C, **B**), 33.51 (C-3', **B**), 33.77 (C-3', **A**), 44.83 (C-2, **B**), 45.05 (C-2, **A**), 45.61 (C-1', **A**), 47.44 (C-1', **B**), 48.25 (CH₂Ph, **B**), 51.95 (CH₂Ph, **A**), 57.69 (C-4', **B**), 57.89 (C-4', **A**), 126.52 (Ph-CH), 127.46 (Ph-CH), 127.81 (Ph-CH), 128.29 (Ph-CH), 128.76 (Ph-CH), 129.10 (Ph-CH), 137.24 (Ph-C, **A**), 138.31 (Ph-C, **B**), 172.12 (amide CO, **B**), 172.58 (amide CO, **A**) ppm—MS (EI, 70 eV): *m/z* (%) = 219.2/218.2/217.2 [M-C₆H₁₁O]⁺ (3/17/59), 121.1/120.1 [C₈H₁₀N]⁺ (5/52), 107.1/106.1 [C₇H₈N]⁺ (4/17), 92.1/91.0 [C₇H₇]⁺ (9/100)—HRMS (ESI) calcd. [M+H]⁺ 317.23359; found 317.23360.

N-(4-Aminopentyl)-*N*-benzyl-3,3-dimethylbutanamide (**35**). PPh₃ (175.2 mg, 0.67 mmol) was added to a solution of azide **34** (175.0 mg, 0.55 mmol) in MeOH (dry, 10 mL) and stirred over night at 25°C. The suspension was concentrated and purified with flash column chromatography on deactivated silica gel (DCM/MeOH 20 : 1) to obtain compound **35** (143.2 mg, 0.49 mmol, and 89%) as colorless oil. IR (ATR-FTIR): $\tilde{\nu}$ = 2950 (m), 2865 (m), 2360 (w), 2341 (w), 1633 (s), 1584 (m), 1494 (w), 1463 (m), 1451 (m), 1388 (m), 1361 (m), 1325 (w), 1277 (w), 1230 (m), 1186 (m), 1153 (w), 1120 (m), 1078 (w), 1028 (w), 955 (w), 892 (w), 815 (w), 730 (m), 699 (m), 633 (w), 619 (w) cm⁻¹—¹H-NMR (600 MHz, CDCl₃): δ = 1.03–1.06 (m, 24 H, *t*Bu-Me, Me), 1.23–1.27 (m, 2 H, 3'-CH₂, **A**), 1.29–1.34 (m, 2 H, 3'-CH₂, **B**), 1.47–1.61 (m, 4 H, 2'-CH₂), 2.23 (s, 2 H, 2-CH₂, **B**), 2.28 (s, 2 H, 2-CH₂, **A**), 2.83–2.87 (m, 1 H, 4'-H, **A**), 2.88–2.94 (m, 1 H, 4'-H, **B**), 3.20 (t, ³*J*_{H-H} = 7.74 Hz, 2 H, 1'-CH₂, **A**), 3.25–3.30 (m, 1 H, 1'-CH₂, **B**), 3.32–3.37 (m, 1 H, 1'-CH₂, **B**), 4.54 (s, 2 H, CH₂Ph, **B**), 4.59 (s, 2 H, CH₂Ph, **A**), 7.16 (d, ³*J*_{H-H} = 7.38 Hz, 2 H, Ph-H), 7.22–7.24 (m, 3 H, Ph-H), 7.25–7.29 (m, 3 H, Ph-H), 7.32–7.34

(m, 2 H, Ph-H) ppm— ^{13}C -NMR (150 MHz, CDCl_3): δ = 23.65 (Me, **B**), 24.02 (Me, **A**), 24.62 (C-2', **B**), 25.69 (C-2', **A**), 30.25 (tBu-Me, **B**), 30.35 (tBu-Me, **A**), 31.71 (tBu-C, **B**), 31.80 (tBu-C, **A**), 36.87 (C-3', **B**), 36.94 (C-3', **A**), 44.83 (C-2, **A**), 45.06 (C-2, **B**), 46.25 (C-1', **B**), 46.96 (C-4', **A**), 47.04 (C-4', **B**), 47.91 (C-1', **A**), 48.26 (CH_2Ph , **A**), 52.11 (CH_2Ph , **B**), 126.51 (Ph-CH), 127.38 (Ph-CH), 127.75 (Ph-CH), 128.26 (Ph-CH), 128.70 (Ph-CH), 129.06 (Ph-CH), 137.34 (Ph-C, **B**), 138.43 (Ph-C, **A**), 172.15 (amide CO, **A**), 172.54 (amide CO, **B**) ppm—MS (EI, 70 eV): m/z (%) = 290.2 $[\text{M}]^{+}$ (4), 275.2 $[\text{M}-\text{CH}_3]^{+}$ (8), 248.2/247.2 $[\text{M}-\text{C}_3\text{H}_7]^{+}$ (9/46), 192.2/191.2 $[\text{M}-\text{C}_6\text{H}_{11}\text{O}]^{+}$ (10/68), 121.1/120.1 $[\text{C}_8\text{H}_{10}\text{N}]^{+}$ (3/36), 92.1/91.1 $[\text{C}_7\text{H}_7]^{+}$ (10/100)—HRMS (ESI) calcd. $[\text{M}+\text{H}]^{+}$ 291.24309; found 291.24319.

2-(4'-Bromopentyl)isoindoline-1,3-dione (36) [33, 38]. (*rac*)-1,4-Dibromopentane (10.122 g, 0.044 mol, and 6.0 mL) was added to a suspension of potassium phthalimide (6.050 g, 0.033 mol) in acetone (35 mL) at 25°C and heated up to 80°C for 24 hours. The suspension was filtered and concentrated and the residue was distilled to give compound **36** (6.806 g, 0.023 mol, and 70%) as light yellow oil. Bp 180°C (3.4×10^{-1} mbar)—IR (ATR-FTIR): $\tilde{\nu}$ = 2955 (w), 2938 (w), 2864 (w), 1771 (w), 1702 (s), 1615 (w), 1465 (w), 1433 (m), 1394 (s), 1376 (m), 1360 (s), 1322 (m), 1303 (w), 1286 (w), 1264 (m), 1243 (m), 1186 (m), 1169 (w), 1157 (w), 1138 (w), 1127 (m), 1083 (m), 1034 (s), 994 (w), 972 (w), 926 (m), 897 (w), 882 (m), 831 (w), 795 (w), 776 (m), 712 (s), 693 (m), 648 (s), 604 (m) cm^{-1} — ^1H -NMR (400 MHz, CDCl_3): δ = 1.68 (d, $^3J_{\text{H-H}}$ = 6.68 Hz, Me), 1.76–1.95 (m, 4 H, 2'- CH_2 , 3'- CH_2), 3.68–3.72 (m, 2 H, 1'- CH_2), 4.10–4.18 (m, 1 H, 4'-CH), 7.69–7.71 (m, 2 H, ar-H), 7.82–7.84 (m, 2 H, ar-H) ppm— ^{13}C -NMR (100 MHz, CDCl_3): δ = 26.66, 27.22, 37.39, 38.31, 50.69 (C-4'), 123.48 (ar-CH), 132.30 (ar-Cq), 134.19 (ar-CH), 168.59 (imide CO) ppm— ^{15}N -NMR (40.5 MHz, $\text{DMSO}-d_6$): -219.0 (N-2) ppm—MS (EI, 70 eV): m/z (%) = 295.1 $[\text{M}]^{+}$ (4), 216.1 $[\text{M}-\text{Br}]^{+}$ (74), 160.0 $[\text{M}-(\text{CH}_2)_2\text{CHBrCH}_3]^{+}$ (100)—CHN calcd. for $\text{C}_{13}\text{H}_{14}\text{BrNO}_2$: C: 52.72 H: 4.76 N: 4.73; found C: 53.64 H: 4.66 N: 4.96.

2,2'-(Pentane-1'',4''-diyl)diisoindoline-1,3-dione (31). The distillation residue was further purified using flash column chromatography on silica gel (using gradients from petroleum ether/EtOAc 5:1 to EE 100% to $\text{CH}_2\text{Cl}_2/\text{MeOH}$ 10:1) and the obtained solid was recrystallized (DCM/petroleum ether) to obtain compound **31** (599.2 mg, 1.65 mmol, 5%) as light yellow crystals. Mp 147°C (DCM/petroleum ether)—IR (ATR-FTIR): $\tilde{\nu}$ = 2971 (w), 2933 (w), 2877 (w), 1769 (w), 1757 (w), 1696 (s), 1611 (w), 1463 (m), 1437 (w), 1391 (m), 1378 (m), 1357 (m), 1327 (m), 1284 (w), 1265 (w), 1243 (w), 1186 (w), 1168 (w), 1139 (w), 1113 (w), 1085 (w), 1059 (s), 1015 (m), 982 (m), 970 (m), 935 (w), 886 (m), 846 (w), 827 (w), 797 (m), 755 (w), 718 (s), 709 (s), 614 (m) cm^{-1} — ^1H -NMR (600 MHz, CDCl_3): δ = 1.45 (d, $^3J_{\text{H-H}}$ = 6.96 Hz, 3 H, Me), 1.53–1.69 (m, 2 H, 2''- CH_2), 1.73–1.79 (m, 1 H, 3''-H), 2.07–2.14 (m, 1 H, 3''-H), 3.62–3.71 (m, 2 H, 1''- CH_2), 4.34–4.40 (m, 1 H, 4''-H), 7.66–7.68 (m, 4 H, 5-H, 6-H, 5'-H, 6'-H), 7.77–7.79 (m, 4 H, 4-H, 7-H, 4'-H, 7'-H) ppm— ^{13}C -NMR

(150 MHz, CDCl_3): δ = 18.86 (Me), 26.17 (C-2''), 31.10 (C-3''), 37.65 (C-1''), 47.13 (C-4''), 123.32 (CH), 123.41 (ar-CH), 132.10 (ar-Cq), 132.27 (ar-Cq), 134.07 (ar-CH), 134.10 (ar-CH), 168.56 (imide CO), 168.66 (imide CO) ppm—MS (EI, 70 eV): m/z (%) = 363.3/362.3 $[\text{M}]^{+}$ (6/26), 175.1/174.1 $[\text{C}_{10}\text{H}_8\text{NO}_2]^{+}$ (14/100), 161.1/160.1 $[\text{C}_9\text{H}_6\text{NO}_2]^{+}$ (5/30)—HRMS (ESI) calcd. $[\text{M}+\text{H}]^{+}$ 363.13393; found 363.13394.

(E)-2-(Pent-3'-enyl)isoindoline-1,3-dione (37). The elimination product **37** was also obtained within the synthesis of **36** as colorless crystals (with varying yields). Mp. 64–67°C (petroleum ether/EtOAc)—IR (ATR-FTIR): $\tilde{\nu}$ = 3063 (w), 3022 (w), 2965 (w), 2938 (w), 2914 (w), 2853 (w), 2159 (w, br), 2026 (w), 1976 (w), 1766 (m), 1698 (s), 1614 (m), 1595 (w), 1467 (w), 1445 (m), 1433 (m), 1394 (s), 1359 (m), 1331 (m), 1289 (w), 1265 (w), 1239 (w), 1188 (m), 1172 (m), 1150 (w), 1061 (m), 1028 (w), 990 (m), 961 (m), 903 (w), 865 (m), 790 (m), 750 (w), 717 (s), 621 (m) cm^{-1} — ^1H -NMR (400 MHz, CDCl_3): δ = 1.56–1.58 (m, 3 H, Me), 2.31–2.36 (m, 2 H, 2'- CH_2), 3.67–3.71 (m, 2 H, 1'- CH_2), 5.34–5.51 (m, 2 H, 3'-H, 4'-H), 7.67–7.69 (m, 2 H, ar-H), 7.80–7.82 (m, 2 H, ar-H) ppm— ^{13}C -NMR (100 MHz, CDCl_3): δ = 18.11 (Me), 31.91 (2'- CH_2), 38.07 (1'- CH_2), 123.37 (ar-CH), 127.08 (ar-CH), 128.34 (ar-CH), 132.28 (ar-Cq), 134.03 (ar-CH), 168.55 (imide CO) ppm—MS (EI, 70 eV): m/z (%) = 216.1/215.1 $[\text{M}]^{+}$ (3/19), 161.1/160.1 $[\text{M}-\text{C}_4\text{H}_7]^{+}$ (15/100)—CHN calcd. for $\text{C}_{13}\text{H}_{13}\text{NO}_2$: C: 72.54 H: 6.09 N: 6.51; found C: 72.22 H: 5.99 N: 6.59.

2-(4'-Azidopentyl)isoindoline-1,3-dione (39). The bromine derivative **36** (606.3 mg, 2.047 mmol) and NaN_3 (406.5 mg, 6.253 mmol) were stirred in DMF (dry, 5 mL) at 25°C for 24 hours under nitrogen atmosphere. The solvent was removed with high vacuum and the residue was purified by filtration through a short column of basic alumina (activity level V, DCM 100%) to give **39** (476.1 mg, 1.843 mmol, and 90%) as a colorless, semisolid compound. Mp 64–66°C (DCM)—IR (ATR-FTIR): $\tilde{\nu}$ = 2933 (w, br), 2097 (m), 1773 (w), 1704 (s), 1614 (w), 1466 (w), 1436 (w), 1395 (m), 1360 (m), 1333 (m), 1267 (w), 1243 (m), 1187 (w), 1171 (w), 1118 (w), 1087 (w), 1048 (m), 1012 (w), 998 (w), 934 (w), 902 (w), 883 (m), 841 (w), 794 (w), 717 (s), 693 (w), 638 (w), 619 (w) cm^{-1} — ^1H -NMR (400 MHz, CDCl_3): δ = 1.24 (d, $^3J_{\text{H-H}}$ = 6.52 Hz, 3 H, Me), 1.46–1.53 (m, 2 H, 3'- CH_2), 1.66–1.86 (m, 2 H, 2'- CH_2), 3.43–3.52 (m, 1 H, 4'-H), 3.68 (t, $^3J_{\text{H-H}}$ = 7.08 Hz, 2 H, 1'- CH_2), 7.68–7.70 (m, 2 H, ar-H), 7.81–7.83 (m, 2 H, ar-H) ppm— ^{13}C -NMR (100 MHz, CDCl_3): δ = 19.60 (Me), 25.49 (C-2'), 33.61 (C-3'), 37.73 (C-1'), 57.65 (C-4'), 123.47 (ar-CH), 132.30 (ar-Cq), 134.18 (ar-CH), 168.59 (imide CO) ppm—MS (EI, 70 eV): m/z (%) = 216.1/215.1 $[\text{M}-\text{HN}_3]^{+}$ (4/15), 161.1/160.1 $[\text{M}-\text{C}_4\text{H}_8\text{N}_3]^{+}$ (18/100)—CHN calcd. for $\text{C}_{13}\text{H}_{14}\text{N}_4\text{O}_2$: C: 60.45 H: 5.46 N: 21.69; found C: 58.62 H: 4.98 N: 22.28.

Conflict of Interests

The author declares no competing financial interest regarding the publication of this paper.

Acknowledgments

This work was supported by the Deutsche Forschungsgemeinschaft (SFB 630 “Recognition, Preparation, and Functional Analysis of Agents against Infectious Diseases”). The author wants to thank Professor Dr. Dr. h.c. mult. Gerhard Bringmann for his support on this work, the group of Professor Dr. Heidrun Moll and Dr. Uta Schurig at Würzburg University (*L. major*) and the group of Professor Dr. Reto Brun (*L. donovani*) at the Swiss Tropical and Public Health Institute in Basel for conducting the bioactivity experiments, and Dr. Madhavan Narayanan for the review of the paper.

References

- [1] World Health Organization, *Scaling up the Response to Infectious Diseases—A Way out of Poverty*, 2002, <http://www.who.int/infectious-disease-report/pages/textonly.html>.
- [2] H. Schlender, J. Schilling, A. Schweizer, and A. Bolz, *Infektionsforschung*, Bundesministerium für Bildung und Forschung, 2009.
- [3] E. F. da Cunha, T. C. Ramalho, D. T. Mancini, and M. P. Freitas, “New approaches to the development of anti-protozoan vaccine and drug candidates: a review of patents,” in *Chemoinformatics: Directions Toward Combating Neglected Diseases*, pp. 3–32, 2012.
- [4] N. Aulner, A. Danckaert, E. Rouault-Hardoin et al., “High content analysis of primary macrophages hosting proliferating leishmania amastigotes: application to anti-leishmanial drug discovery,” *PLoS Neglected Tropical Diseases*, vol. 7, no. 4, Article ID e2154, 2013.
- [5] J. van Griensven, M. Balasegaram, F. Meheus, J. Alvar, L. Lynen, and M. Boelaert, “Combination therapy for visceral leishmaniasis,” *The Lancet Infectious Diseases*, vol. 10, no. 3, pp. 184–194, 2010.
- [6] F. Astelbauer and J. Walochnik, “Antiprotozoal compounds: state of the art and new developments,” *International Journal of Antimicrobial Agents*, vol. 38, no. 2, pp. 118–124, 2011.
- [7] World Health Organization, *Leishmaniasis—situation and trends*, 2014, http://www.who.int/gho/neglected_diseases/leishmaniasis/en.
- [8] M. Niedrig, B. Reinhardt, G.-D. Burchard et al., “Leishmaniose,” in *Steckbriefe seltener und importierter parasitärer Erkrankungen*, pp. 120–122, Robert Koch Institute, 2006, http://www.bsafb.de/fileadmin/downloads/downloads_07/importierte_Infektionskrh_RKI.pdf.
- [9] P. A. Bates, “Transmission of *Leishmania* metacyclic promastigotes by phlebotomine sand flies,” *International Journal for Parasitology*, vol. 37, no. 10, pp. 1097–1106, 2007.
- [10] R. J. S. Burchmore and M. P. Barrett, “Life in vacuoles—nutrient acquisition by *Leishmania* amastigotes,” *International Journal for Parasitology*, vol. 31, no. 12, pp. 1311–1320, 2001.
- [11] G. de Muylder, K. K. H. Ang, S. Chen, M. R. Arkin, J. C. Engel, and J. H. McKerrow, “A screen against leishmania intracellular amastigotes: comparison to a promastigote screen and identification of a host cell-specific hit,” *PLoS Neglected Tropical Diseases*, vol. 5, no. 7, Article ID e1253, 2011.
- [12] H. W. Murray, J. D. Berman, C. R. Davies, and N. G. Saravia, “Advances in leishmaniasis,” *The Lancet*, vol. 366, no. 9496, pp. 1561–1577, 2005.
- [13] G. Harms-Zwingerberger and U. Bienzle, “Nach Deutschl and importierte Leishmaniosen,” *Deutsches Ärzteblatt*, vol. 104, pp. A3108–A3113, 2007.
- [14] J. M. Bethony, R. N. Cole, X. Guo et al., “Vaccines to combat the neglected tropical diseases,” *Immunological Reviews*, vol. 239, no. 1, pp. 237–270, 2011.
- [15] <http://www.cdc.gov/travel/yellowbook/2012/chapter-3-infectiousdiseases-related-to-travel/leishmaniasis-cutaneous.htm>.
- [16] L. Monzote, “Antileishmanial patents antileishmanial current drugs and relevant patents,” *Recent Patents on Anti-Infective Drug Discovery*, vol. 6, no. 1, pp. 1–26, 2011.
- [17] J. M. Pérez-Victoria, B. I. Bavchvarov, I. R. Torrecillas et al., “Sitamaquine overcomes ABC-mediated resistance to miltefosine and antimony in *Leishmania*,” *Antimicrobial Agents and Chemotherapy*, vol. 55, no. 8, pp. 3838–3844, 2011.
- [18] Drugs for Neglected Diseases Initiative, *Leishmaniasis—Global View*, 2014, <http://www.dndi.org/diseases-projects/diseases/vl.html>.
- [19] World Health Organization, *Leishmaniasis—Key Facts*, 2014, status, <http://www.who.int/mediacentre/factsheets/fs375/en>.
- [20] B. Pécou, P. Chirac, P. Trouiller, and J. Pinel, “Access to essential drugs in poor countries: a lost battle?” *Journal of the American Medical Association*, vol. 281, no. 4, pp. 361–367, 1999.
- [21] M. Loedige, *Synthesis and evaluation of novel drug classes against infectious diseases [Dissertation]*, Würzburg University, Würzburg, Germany, 2013, <http://bit.ly/1rzOtW7>.
- [22] C. D. Siebert, “Das Bioisosterie-Konzept: Arzneistoffentwicklung,” *Chemie in unserer Zeit*, vol. 38, no. 5, pp. 320–324, 2004.
- [23] A. Fournet, M. E. Ferreira, A. Rojas de Arias et al., “In vivo efficacy of oral and intralésional administration of 2-substituted quinolines in experimental treatment of new world cutaneous leishmaniasis caused by *Leishmania amazonensis*,” *Antimicrobial Agents and Chemotherapy*, vol. 40, no. 11, pp. 2447–2451, 1996.
- [24] N. P. Sahu, C. Pal, N. B. Mandal et al., “Synthesis of a novel quinoline derivative, 2-(2-methylquinolin-4-ylamino)-N-phenylacetamide—a potential antileishmanial agent,” *Bioorganic & Medicinal Chemistry*, vol. 10, no. 6, pp. 1687–1693, 2002.
- [25] M. O. F. Khan, M. S. Levi, B. L. Tekwani, N. H. Wilson, and R. F. Borne, “Synthesis of isoquinuclidine analogs of chloroquine: antimalarial and antileishmanial activity,” *Bioorganic and Medicinal Chemistry*, vol. 15, no. 11, pp. 3919–3925, 2007.
- [26] I. Khan, R. Yasmin, and I. Sidiqi, “Chloroquine in cutaneous leishmaniasis,” *Journal of Pakistan Association of Dermatologists*, vol. 17, no. 2, pp. 95–100, 2007.
- [27] D. Sereno and J.-L. Lemesre, “Asexually cultured amastigote forms as an in vitro model for investigation of antileishmanial agents,” *Antimicrobial Agents and Chemotherapy*, vol. 41, no. 5, pp. 972–976, 1997.
- [28] K. Kaur, S. R. Patel, P. Patil et al., “Synthesis, antimalarial, antileishmanial, antimicrobial, cytotoxicity, and methemoglobin (MetHB) formation activities of new 8-quinolinamines,” *Bioorganic and Medicinal Chemistry*, vol. 15, no. 2, pp. 915–930, 2007.
- [29] J. V. Richard and K. A. Werbovetz, “New antileishmanial candidates and lead compounds,” *Current Opinion in Chemical Biology*, vol. 14, no. 4, pp. 447–455, 2010.
- [30] C. López-Martín, J. M. Pérez-Victoria, L. Carvalho, S. Castanys, and F. Gamarro, “Sitamaquine sensitivity in *Leishmania* species is not mediated by drug accumulation in acidocalcisomes,” *Antimicrobial Agents and Chemotherapy*, vol. 52, no. 11, pp. 4030–4036, 2008.

- [31] V. Yardley, F. Gamarro, and S. L. Croft, "Antileishmanial and antitrypanosomal activities of the 8-aminoquinoline tafenoquine," *Antimicrobial Agents and Chemotherapy*, vol. 54, no. 12, pp. 5356–5358, 2010.
- [32] L. Keller, S. Beaumont, J.-M. Liu et al., "New C5-alkylated indolobenzazepinones acting as inhibitors of tubulin polymerization: cytotoxic and antitumor activities," *Journal of Medicinal Chemistry*, vol. 51, no. 12, pp. 3414–3421, 2008.
- [33] R. C. Elderfield, "Synthesis of primaquine and certain of its analogs," *Journal of the American Chemical Society*, vol. 77, no. 18, pp. 4816–4819, 1955.
- [34] J. J. Berman, "Treatment of leishmaniasis with miltefosine: 2008 status," *Expert Opinion on Drug Metabolism & Toxicology*, vol. 4, no. 9, pp. 1209–1216, 2008.
- [35] G. Bringmann, M. Lödige, R. Benz, A. Kronhardt, C. Beitzinger, and H. Barth, "Aminoquinolinium salts, methods of their production and their use as active agents for biotechnological and medical applications against binary toxins; patent application—priority date 28.09.2010, international filing date 28.09.2011," International Application number PCT/EP2011/004846, WO/2012/041493, 2012.
- [36] F. Ehlgén, J. S. Pham, T. de Koning-Ward, A. F. Cowman, and S. A. Ralph, "Investigation of the *Plasmodium falciparum* food vacuole through inducible expression of the chloroquine resistance transporter (PfCRT)," *PLoS ONE*, vol. 7, no. 6, Article ID e38781, 2012.
- [37] M. V. N. de Souza, K. C. Pais, C. R. Kaiser, M. A. Peralta, M. de L. Ferreira, and M. C. S. Lourenço, "Synthesis and *in vitro* antitubercular activity of a series of quinoline derivatives," *Bioorganic and Medicinal Chemistry*, vol. 17, no. 4, pp. 1474–1480, 2009.
- [38] D. A. Powell and G. C. Fu, "Nickel-catalyzed cross-couplings of organosilicon reagents with unactivated secondary alkyl bromides," *Journal of the American Chemical Society*, vol. 126, no. 25, pp. 7788–7789, 2004.